Compositions and methods for the treatment of pain

SiRNA molecules targeting the SCN9A gene provide a selective and effective treatment for chronic and neuropathic pain by silencing Nav1.7 activity in the central nervous system, addressing the limitations of existing pain medications.

JP2024542738APending Publication Date: 2024-11-15ATALANTA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532733
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-12-01
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Current pain medications, such as pregabalin and duloxetine, have limited efficacy for chronic and neuropathic pain, while opioids are associated with severe side effects and addiction, and existing Nav1.7 inhibitors lack selectivity and central nervous system permeability.

Method used

Development of small interfering RNA (siRNA) molecules that target the SCN9A gene to selectively reduce Nav1.7 activity, administered via various routes to the central nervous system, silencing the gene and reducing pain transmission.

Benefits of technology

The siRNA molecules exhibit high selectivity for SCN9A over other sodium channels, effectively alleviating pain by silencing the gene and preventing noxious stimulus transmission, offering a potential treatment for chronic and neuropathic pain with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542738000076
    Figure 2024542738000076
  • Figure 2024542738000001
    Figure 2024542738000001
  • Figure 2024542738000002
    Figure 2024542738000002
Patent Text Reader

Abstract

The present disclosure provides single-stranded or double-stranded interfering RNA molecules (e.g., siRNAs) targeting the SCN9A gene. The interfering RNA molecules may include specific patterns of nucleoside modifications and internucleoside linkage modifications, as may pharmaceutical compositions comprising them. The siRNA molecules may be branched siRNA molecules, such as bi-, tri-, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5' phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the present disclosure provides methods for delivering the siRNA molecules of the present disclosure to the central nervous system of a subject, such as a subject experiencing pain or identified as having a pain disorder.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to small interfering RNA (siRNA) molecules that target the RNA transcript (e.g., mRNA) of the sodium voltage-dependent channel alpha subunit 9 (SCN9A) gene and compositions containing the same. The present disclosure further describes a method of treating pain (e.g., chronic pain or acute pain) by delivering an SCN9A-targeting siRNA molecule to the central nervous system of a subject in need thereof. [Background technology]

[0002] Pain indications represent a large part of unmet medical need. Among the existing pain medications, pregabalin and duloxetine have very limited efficacy, and opioids are effective for some forms of acute or persistent pain, but are associated with severe respiratory disease liability, gastrointestinal disease liability, and addiction liability. Other pharmacological treatments are sometimes used off-label for neuropathic or chronic pain, but generally have weak efficacy and too many side effects. Therefore, there is much interest in developing new treatments for pain, especially in generating inhibitors of the Nav1.7 voltage-gated sodium ion channel protein, which is encoded by the voltage-gated sodium channel alpha subunit 9 (SCN9A) gene.

[0003] However, the Nav1.7 protein has proven difficult to target. One major difficulty stems from the selectivity required for Nav1.7 inhibitors to be effective therapeutics. Although Nav1.7 itself is not expected to pose significant on-target burden for inhibition, some of the other eight sodium channel paralogs control cellular excitability in brain, cardiac, and skeletal muscles. Because the functional domains of the various sodium channels are highly conserved, few small molecule inhibitors with significant selectivity for Nav1.7 among sodium channel isoforms have been reported. Central nervous system penetration of small molecule Nav1.7-selective inhibitors has also been difficult to achieve.

[0004] Thus, there remains a need for therapeutic agents that can selectively reduce the activity of Nav1.7 relative to other sodium channels in a manner that effectively relieves various forms of pain. Summary of the Invention

[0005] The present disclosure provides compositions and methods for reducing expression of sodium voltage-gated channel alpha subunit 9 (SCN9A) by small interfering RNA (siRNA)-mediated silencing of the SCN9A transcript. The compositions and methods offer the advantage of being highly selective for SCN9A over other central nervous system (CNS) genes, including genes encoding other sodium channel paralogs.

[0006] The siRNA molecules of the present disclosure can be used to silence the SCN9A gene, thereby preventing the translation of the corresponding mRNA transcript and reducing the expression of SCN9A. This reduction in SCN9A levels prevents the transmission of noxious stimuli that cause pain. The siRNA molecules of the present disclosure can be administered to individuals with pain syndromes or individuals identified as having gain-of-function SCN9A mutations. The siRNA molecules of the present disclosure can be delivered directly to the CNS or neurons of a subject who requires SCN9A silencing, for example, by intrathecal, intracerebroventricular, intrastriatal, intraparenchymal, direct injection into specific nerves or ganglia (e.g., trigeminal or dorsal root ganglion), intracisternal injection such as by catheter insertion, intravenous injection, subcutaneous injection, or intramuscular injection.

[0007] In one aspect, the disclosure provides an siRNA molecule comprising an antisense strand and a sense strand having complementarity to the antisense strand. The antisense strand has sufficient complementarity to hybridize to a region in an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152. In some embodiments, the antisense strand has sufficient complementarity to hybridize to a region in an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576. The antisense strand may be, for example, 10 to 50 nucleotides in length (e.g., 10 to 45 nucleotides in length, 10 to 40 nucleotides in length, 10 to 35 nucleotides in length, 10 to 30 nucleotides in length, 10 to 29 nucleotides in length, 10 to 28 nucleotides in length, 10 to 27 nucleotides in length, 10 to 26 nucleotides in length, 10 to 25 nucleotides in length, 10 to 24 nucleotides in length, 10 to 23 nucleotides in length, 10 to 22 nucleotides in length, 10 to 21 nucleotides in length, or 10 to 20 nucleotides in length). In some embodiments, the antisense strand is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more nucleotides in length.

[0008] In some embodiments of any of the foregoing aspects, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 15 consecutive nucleobases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152. In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 16 consecutive nucleic acid bases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 17 consecutive nucleic acid bases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152. In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 18 consecutive nucleic acid bases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 19 consecutive nucleic acid bases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152. In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 20 consecutive nucleic acid bases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.In some embodiments, the antisense strand has at least 70% (e.g., at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, or 100%) complementarity to a region of 21 consecutive nucleic acid bases within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0009] In some embodiments, the antisense strand has at least 70% (e.g., at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) complementarity to a region within an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0010] In some embodiments, the antisense strand has at least 75% complementarity to a region in an SCN9A mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 385 to 576 and 961 to 1152. For example, the antisense strand may have at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementarity to a region in an SCN9A mRNA transcript having any one of the nucleic acid sequences of SEQ ID NOs: 385 to 576 and 961 to 1152.

[0011] In some embodiments, the antisense strand has at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0012] In some embodiments, the antisense strand has 10 to 30 contiguous nucleotides (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0013] In some embodiments, the antisense strand has 12 to 30 contiguous nucleotides (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0014] In some embodiments, the antisense strand has 15 to 30 contiguous nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0015] In some embodiments, the antisense strand has 18 to 30 contiguous nucleotides (e.g., 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0016] In some embodiments, the antisense strand has 18 to 25 contiguous nucleotides (e.g., 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0017] In some embodiments, the antisense strand has 18 to 21 contiguous nucleotides (e.g., 18, 19, 20, or 21 contiguous nucleotides) that are fully complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0018] In some embodiments, the antisense strand has 21 contiguous nucleotides that are fully complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0019] In some embodiments, the antisense strand has 21 to 30 contiguous nucleotides (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0020] In some embodiments, the antisense strand has 24 to 30 contiguous nucleotides (e.g., 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides) that are completely complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0021] In some embodiments, the antisense strand has 30 contiguous nucleotides that are fully complementary to a contiguous polynucleotide segment of equal length within a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0022] In some embodiments, the antisense strand has 9 or fewer nucleotide mismatches to a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152, and optionally the antisense strand contains 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or only 1 mismatch to a region of an SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

[0023] In some embodiments of any of the aforementioned aspects or embodiments of the disclosure, the region of the SCN9A RNA transcript has the nucleic acid sequence of any one of SEQ ID NOs: 385-576. In some embodiments of any of the aforementioned aspects or embodiments of the disclosure, the region of the SCN9A RNA transcript has the nucleic acid sequence of SEQ ID NO: 970 or 1072.

[0024] In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-192. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO: 586 or 688.

[0025] In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-192. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 586 or 688.

[0026] In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 1-192 and 577-768, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1-192 and 577-768. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to any one of the nucleic acid sequences of SEQ ID NOs: 1-192, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1-192. In some embodiments, the antisense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO:586 or 688, and optionally the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of SEQ ID NO:586 or 688.

[0027] In some embodiments, the antisense strand has the nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768. In some embodiments, the antisense strand has the nucleic acid sequence of any one of SEQ ID NOs: 1-192. In some embodiments, the antisense strand has the nucleic acid sequence of SEQ ID NO: 586 or 688.

[0028] In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960. In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384. In some embodiments, the sense strand has a nucleic acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO:778 or 880.

[0029] In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960. In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384. In some embodiments, the sense strand has a nucleic acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO:778 or 880.

[0030] In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960, and optionally, the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960. In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384, and optionally, the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of any one of SEQ ID NOs: 193-384. In some embodiments, the sense strand has a nucleic acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of SEQ ID NO: 778 or 880, and optionally the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of SEQ ID NO: 778 or 880.

[0031] In some embodiments, the siRNA molecule has a sense strand having the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960. In some embodiments, the siRNA molecule has a sense strand having the nucleic acid sequence of any one of SEQ ID NOs: 193-384. In some embodiments, the siRNA molecule has a sense strand having the nucleic acid sequence of SEQ ID NO: 778 or 880.

[0032] In some embodiments, the antisense strand has a structure represented by Formula I, which in the 5'-3' direction is: AB-(A') j -CP 2 -DP 1 -(C'-P 1 ) k -C' Formula I; where A is of the formula CP 1 -DP 1 Represented by; Each A' has the formula CP 2 -DP 2 Represented by; B is the formula CP 2 -DP 2 -DP 2 -DP 2 Represented by; each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0033] In some embodiments, the antisense strand has a structure represented by Formula A1, which, in the 5'-3' direction, is: ASBSAOBOBOBOAOBOAOBOA-OBOAOBOAOBSASASASBSA Formula A1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0034] In some embodiments, the antisense strand has a structure represented by Formula II, which, in the 5'-3' direction, is: AB-(A') j -CP 2 -DP 1 -(CP 1 ) k -C' Formula II; where A is of the formula CP 1 -DP 1 Represented by; Each A' has the formula CP 2 -DP 2 Represented by; B is the formula CP 2 -DP 2 -DP 2 -DP 2 Represented by; each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0035] In some embodiments, the antisense strand has a structure represented by Formula A2, which, in the 5'-3' direction, is: ASBSAOBOBOBOAOBOAOBOA-OBOAAOBOAOBSASASASASA Formula A2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0036] In some embodiments, the sense strand has a structure represented by Formula III, which, in the 5'-3' direction, is: E-(A') m -F Formula III; In the formula, E is a compound represented by the formula (CP 1 )2; F is the formula (CP 2 )3-DP 1 -CP 1 -C, (CP 2 )3-DP 2 -CP 2 -C, (CP 2 )3-DP 1 -CP 1 -D, or (CP 2 )3-DP 2 -CP 2 - represented by D; A', C, D, P 1 , and P 2 is as defined in formula II; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0037] In some embodiments, the sense strand has a structure represented by formula S1, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBBSASA Formula S1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0038] In some embodiments, the sense strand has a structure represented by formula S2, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOA Formula S2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0039] In some embodiments, the sense strand has a structure represented by formula S3, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBSASB formula S3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0040] In some embodiments, the sense strand has a structure represented by formula S4, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOB Equation S4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0041] In some embodiments, the antisense strand has a structure represented by Formula IV, which, in the 5'-3' direction, is: A-(A') j -CP 2 -B-(CP 1 ) k -C' Formula IV; where A is of the formula CP 1 -DP 1 Represented by; Each A' has the formula CP 2 -DP 2 Represented by; B is the formula DP 1 -CP 1 -DP 1 Represented by; each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0042] In some embodiments, the antisense strand has a structure represented by Formula A3, which, in the 5'-3' direction, is: ASBSAOBOAOBOAOBOAOBOA-OBOAOBOAOBSASASASA formula A3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0043] In some embodiments, the sense strand has a structure represented by Formula V, where in the 5'-3' direction, Formula V is: E-(A') m -CP 2 -F formula V; In the formula, E is a compound represented by the formula (CP 1 )2; F is the formula DP 1 -CP 1 -C, D.P. 2 -CP 2 -C, D.P. 1 -CP 1 -D, or DP 2 -CP 2 - represented by D; A', C, D, P 1 , and P 2 is as defined in formula IV; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0044] In some embodiments, the sense strand has a structure represented by formula S5, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASA Formula S5; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0045] In some embodiments, the sense strand has a structure represented by formula S6, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOA Formula S6; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0046] In some embodiments, the sense strand has a structure represented by formula S7, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASB Formula S7; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0047] In some embodiments, the sense strand has a structure represented by formula S8, which, in the 5'-3' direction, is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOB formula S8; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0048] In some embodiments, the antisense strand has a structure represented by Formula VI, which in the 5'-3' direction is: A.B. j -EB k -EFG l -DP 1 -C' Formula VI; where A is of the formula CP 1 -DP1 Represented by; Each B is a function of the formula CP 2 Represented by; each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each E is a function of the formula DP 2 -CP 2 Represented by; F is the formula DP 1 -CP 1 Represented by; Each G has the formula CP 1 Represented by; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); l is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0049] In some embodiments, the antisense strand has a structure represented by Formula A4, which, in the 5'-3' direction, is: ASBSAOAOAOBOAOAOAOAOA-OAOAOBOAOBSASASASBSA formula A4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0050] In some embodiments, the sense strand has a structure represented by Formula VII, which, in the 5'-3' direction, is: HBm -I n -A'-B o -HC Formula VII; where A' is a compound of the formula CP 2 -DP 2 Represented by; Each H is a function of the formula (CP 1 )2; Each I is independently represented by the formula (DP 2 ) is represented as; B, C, D, P 1 , and P 2 is as defined in formula VI; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); n is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); o is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7).

[0051] In some embodiments, the sense strand has a structure represented by formula S9, which, in the 5'-3' direction, is: ASASAOAOAOBOBOBOAOBOA-OAOAOAASASA Formula S9; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0052] In some embodiments, the antisense strand also has a 5' phosphorus stabilizing moiety at the 5' end of the antisense strand.

[0053] In some embodiments, the sense strand also has a 5' phosphorus stabilizing moiety at the 5' end of the sense strand.

[0054] In some embodiments, each 5′ phosphorus stabilizing moiety is independently represented by any one of formulas IX, XX, XI, XII, XIII, XIV, XV, or XVI: [ka] wherein Nuc represents a nucleobase, optionally the nucleobase is selected from the group consisting of adenine, uracil, guanine, thymine, and cytosine, and R represents an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, phenyl, benzyl, a cation (e.g., a monovalent cation), or hydrogen.

[0055] In some embodiments, the nucleobase is adenine, uracil, guanine, thymine, or cytosine.

[0056] In some embodiments, the 5' phosphorus stabilizing moiety is an (E)-vinyl phosphonate of formula XI.

[0057] In some embodiments, the siRNA molecule also has a hydrophobic portion at the 5' or 3' end of the siRNA molecule.

[0058] In some embodiments, the hydrophobic moiety is selected from the group consisting of cholesterol, vitamin D, or tocopherol.

[0059] In some embodiments, the siRNA molecule is a branched siRNA molecule.

[0060] In some embodiments, the branched siRNA molecule is biantennary, triantennary, or tetraantennary.

[0061] In some embodiments, the siRNA molecule is biantennary, and optionally the biantennary siRNA molecule is represented by any one of Formulas XVII, XVIII, or XIX: [ka] wherein each RNA is independently a siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

[0062] In some embodiments, the biantennary siRNA molecule is represented by formula XVII. In some embodiments, the biantennary siRNA molecule is represented by formula XVIII. In some embodiments, the biantennary siRNA molecule is represented by formula XIX.

[0063] In some embodiments, the siRNA molecule is tri-antennary, and optionally the tri-antennary siRNA molecule is represented by any one of Formulas XX, XXI, XXII, or XXIII: [ka] wherein each RNA is independently a siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

[0064] In some embodiments, the three-branched siRNA molecule is represented by formula XX. In some embodiments, the three-branched siRNA molecule is represented by formula XXI. In some embodiments, the three-branched siRNA molecule is represented by formula XXII. In some embodiments, the three-branched siRNA molecule is represented by formula XXIII.

[0065] In some embodiments, the siRNA molecule is tetraantennary, and optionally the tetraantennary siRNA molecule is represented by any one of Formulas XXIV, XXV, XXVI, XXVII, or XXVIII: [ka] wherein each RNA is independently a siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

[0066] In some embodiments, the four-branched siRNA molecule is represented by formula XXIV. In some embodiments, the four-branched siRNA molecule is represented by formula XXV. In some embodiments, the four-branched siRNA molecule is represented by formula XXVI. In some embodiments, the four-branched siRNA molecule is represented by formula XXVII. In some embodiments, the four-branched siRNA molecule is represented by formula XXVIII.

[0067] In some embodiments of the branched siRNA, the linker is selected from the group consisting of one or more consecutive subunits of ethylene glycol (e.g., polyethylene glycol (PEG), e.g., triethylene glycol (TrEG) or tetraethylene glycol (TEG)), alkyl, carbohydrate, block copolymer, peptide, RNA, and DNA.

[0068] In some embodiments, the linker is an ethylene glycol oligomer. In some embodiments, the linker is an alkyl oligomer. In some embodiments, the linker is a carbohydrate oligomer. In some embodiments, the linker is a block copolymer. In some embodiments, the linker is a peptide oligomer. In some embodiments, the linker is an RNA oligomer. In some embodiments, the linker is a DNA oligomer.

[0069] In some embodiments, the ethylene glycol oligomer is PEG. In some embodiments, the PEG is TrEG. In some embodiments, the PEG is TEG.

[0070] In some embodiments, the oligomer or copolymer contains between 2 and 20 consecutive subunits (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive subunits).

[0071] In some embodiments, the linker joins one or more (eg, 1, 2, 3, 4, or more) siRNA molecules via a covalent bond-forming moiety.

[0072] In some embodiments, the covalent bond forming moiety is selected from the group consisting of alkyl, ester, amide, carbamate, phosphonate, phosphate, phosphorothioate, phosphoramidate, triazole, urea, and formacetal.

[0073] In some embodiments, the linker comprises a structure of formula L1. [ka]

[0074] In some embodiments, the linker comprises a structure of formula L2. [ka]

[0075] In some embodiments, the linker comprises a structure of formula L3. [ka]

[0076] In some embodiments, the linker comprises a structure of formula L4. [ka]

[0077] In some embodiments, the linker comprises a structure of formula L5. [ka]

[0078] In some embodiments, the linker comprises a structure of formula L6. [ka]

[0079] In some embodiments, the linker comprises a structure of formula L7. [ka]

[0080] In some embodiments, the linker comprises a structure of formula L8. [ka]

[0081] In some embodiments, the linker comprises a structure of formula L9. [ka] (Formula L9)

[0082] In some embodiments of any of the siRNA molecules described herein, 50% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109, 104, 105, 106, 107, 108, 109 ... %, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% can be 2'-O-Me ribonucleotides.

[0083] In some embodiments, 60% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).

[0084] In some embodiments, 70% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).

[0085] In some embodiments, 80% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).

[0086] In some embodiments, 90% or more of the ribonucleotides in the antisense strand are 2'-O-Me ribonucleotides (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the ribonucleotides in the antisense strand can be 2'-O-Me ribonucleotides).

[0087] In some embodiments, 10% or less of the internucleoside linkages are phosphodiester or phosphorothioate linkages. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the internucleoside linkages are phosphodiester or phosphorothioate linkages. In some embodiments, 100% of the internucleoside linkages are phosphodiester or phosphorothioate linkages.

[0088] In some embodiments, 9 of the internucleoside linkages are phosphodiester or phosphorothioate linkages.

[0089] In some embodiments, the length of the antisense strand is between 10 and 30 nucleotides (e.g., 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), between 15 and 25 nucleotides (e.g., 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides), or between 18 and 23 nucleotides (e.g., 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides). In some embodiments, the length of the antisense strand is 20 nucleotides. In some embodiments, the length of the antisense strand is 21 nucleotides. In some embodiments, the length of the antisense strand is 22 nucleotides. In some embodiments, the length of the antisense strand is 23 nucleotides. In some embodiments, the length of the antisense strand is 24 nucleotides. In some embodiments, the length of the antisense strand is 25 nucleotides. In some embodiments, the length of the antisense strand is 26 nucleotides. In some embodiments, the length of the antisense strand is 27 nucleotides. In some embodiments, the length of the antisense strand is 28 nucleotides. In some embodiments, the length of the antisense strand is 29 nucleotides. In some embodiments, the length of the antisense strand is 30 nucleotides.

[0090] In some embodiments, the siRNA molecules of the branched compound are linked together by a linker (e.g., ethylene glycol oligomer, such as tetraethylene glycol). In some embodiments, the siRNA molecules of the branched compound are linked together via a linker between the sense strand of one siRNA molecule and the sense strand of the other siRNA molecule. In some embodiments, the siRNA molecules are linked together via a linker between the antisense strand of one siRNA molecule and the antisense strand of the other siRNA molecule. In some embodiments, the siRNA molecules of the branched compound are linked together via a linker between the sense strand of one siRNA molecule and the antisense strand of the other siRNA molecule.

[0091] In some embodiments, the length of the sense strand is between 12 and 30 nucleotides (e.g., 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), or between 14 and 18 nucleotides (e.g., 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, or 18 nucleotides). In some embodiments, the length of the sense strand is 15 nucleotides. In some embodiments, the length of the sense strand is 16 nucleotides. In some embodiments, the length of the sense strand is 17 nucleotides. In some embodiments, the length of the sense strand is 18 nucleotides. In some embodiments, the length of the sense strand is 19 nucleotides. In some embodiments, the length of the sense strand is 20 nucleotides. In some embodiments, the length of the sense strand is 21 nucleotides. In some embodiments, the length of the sense strand is 22 nucleotides. In some embodiments, the sense strand is 23 nucleotides in length. In some embodiments, the sense strand is 24 nucleotides in length. In some embodiments, the sense strand is 25 nucleotides in length. In some embodiments, the sense strand is 26 nucleotides in length. In some embodiments, the sense strand is 27 nucleotides in length. In some embodiments, the sense strand is 28 nucleotides in length. In some embodiments, the sense strand is 29 nucleotides in length. In some embodiments, the sense strand is 30 nucleotides in length.

[0092] In some embodiments, the four internucleoside linkages are phosphorothioate linkages.

[0093] In some embodiments of the siRNA molecules described herein, the antisense strand is 18 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 18 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 19 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 20 nucleotides long and the sense strand is 20 nucleotides long.In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 21 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 22 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 14 nucleotides long.In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 23 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 22 nucleotides long.In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 24 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 25 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 17 nucleotides long.In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 26 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 25 nucleotides long.In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 27 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 28 nucleotides long and the sense strand is 28 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 14 nucleotides long.In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 16 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 28 nucleotides long. In some embodiments, the antisense strand is 29 nucleotides long and the sense strand is 29 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 14 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 15 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 16 nucleotides long.In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 17 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 18 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 19 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 20 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 21 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 22 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 23 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 24 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 25 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 26 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 27 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 28 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 29 nucleotides long. In some embodiments, the antisense strand is 30 nucleotides long and the sense strand is 30 nucleotides long.

[0094] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an siRNA molecule of any of the preceding aspects or embodiments of the present disclosure and a pharma- ceutically acceptable excipient, carrier, or diluent.

[0095] In a further aspect, the present disclosure provides a method of delivering an siRNA molecule to the CNS or neurons of a subject experiencing pain or diagnosed as having pain or a pain disorder by administering to the subject a therapeutically effective amount of an siRNA molecule or pharmaceutical composition of any of the preceding aspects or embodiments of the present disclosure.

[0096] In a further aspect, the present disclosure provides a method of treating pain or a pain disorder in a subject in need thereof by administering to the CNS or neuron of the subject a therapeutically effective amount of a siRNA molecule or pharmaceutical composition of any of the preceding aspects or embodiments of the present disclosure.

[0097] In some embodiments, the pain is neuropathic pain.

[0098] In some embodiments, the pain is nociceptive pain.

[0099] In some embodiments, the pain is post-operative pain, in some embodiments, the pain is persistent pain, in some embodiments, the pain is inflammatory pain.

[0100] In some embodiments, the pain disorder is Gerhardt's disease, Mitchell's disease, or Weir-Mitchell disease. In some embodiments, the subject has been diagnosed with erythromelalgia.

[0101] In another aspect, the present disclosure provides a method of reducing SCN9A expression in a subject in need thereof by administering to the CNS or neuron of the subject a therapeutically effective amount of an siRNA or pharmaceutical composition of any of the preceding aspects or embodiments of the disclosure.

[0102] In some embodiments, upon administration of the siRNA molecule or pharmaceutical composition of any of the foregoing aspects or embodiments of the present disclosure, the subject exhibits selective reduction in SCN9A expression relative to reduced expression of one or more other voltage-gated sodium ion channel genes.

[0103] In some embodiments, the siRNA molecule or pharmaceutical composition is administered to the subject by intrathecal injection or other delivery to the central nervous system.

[0104] In some embodiments, the subject is a human.

[0105] In another aspect, the present disclosure provides a kit having an siRNA molecule or pharmaceutical composition of any of the preceding aspects or embodiments of the disclosure and a package insert instructing a user of the kit to carry out a method of any of the preceding aspects or embodiments of the disclosure. [Brief description of the drawings]

[0106] [Figure 1] Graph showing IC50 measurements of two exemplary siRNA molecules of the present disclosure: (1) having an antisense strand of SEQ ID NO: 688 and a sense strand of SEQ ID NO: 880, with an IC50 of 0.0334 nM, and (2) having an antisense strand of SEQ ID NO: 586 and a sense strand of SEQ ID NO: 778, with an IC50 of 0.0166 nM.

[0107] definition Unless otherwise defined herein, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In case of any potential ambiguity, the definitions provided herein take precedence over any dictionary or external definitions. Unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular. The use of "or" means "and / or" unless otherwise stated. The use of the term "including" as well as other forms such as "include" and "included" are not limiting.

[0108] As used herein, the term "nucleic acid" refers to an RNA or DNA molecule composed of a chain of ribonucleotides or deoxyribonucleotides, respectively.

[0109] As used herein, the term "therapeutic nucleic acid" refers to a nucleic acid molecule (e.g., a ribonucleic acid) that has partial or complete complementarity with, interacts with, and mediates the silencing of expression of a disease-associated target mRNA.

[0110] As used herein, the term "carrier nucleic acid" refers to a nucleic acid molecule (e.g., a ribonucleic acid) that has sequence complementarity with and hybridizes to a therapeutic nucleic acid. As used herein, the term "3' end" refers to the end of a nucleic acid that contains an unmodified hydroxyl group at the 3' carbon of the ribose ring.

[0111] As used herein, the term "nucleoside" refers to a molecule that consists of a heterocyclic base and its sugar.

[0112] As used herein, the term "nucleotide" refers to a nucleoside having a phosphate group on its 3' or 5' sugar hydroxyl group.

[0113] In the context of the present invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages, as well as oligonucleotides having non-naturally occurring (e.g., modified) portions that function similarly. Such modified or substituted oligonucleotides are often preferred over native forms due to desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid targets, and increased stability in the presence of nucleases.

[0114] As used herein, the term "siRNA" refers to small interfering RNA duplexes that induce the RNA interference (RNAi) pathway. siRNA molecules may be of various lengths (generally 10-30 base pairs) and may contain various degrees of complementarity to their target mRNA. The term "siRNA" includes duplexes of two separate strands, and single strands that optionally form a hairpin structure containing a double-stranded region.

[0115] As used herein, the term "antisense strand" refers to the strand of the siRNA duplex that contains a degree of complementarity to a target gene.

[0116] As used herein, the term "sense strand" refers to the siRNA duplex that contains complementarity to the antisense strand.

[0117] The term "interfering RNA molecule" refers to an RNA molecule, such as a small interfering RNA (siRNA), microRNA (miRNA), short hairpin RNA (shRNA), or antisense oligonucleotide (ASO), that inhibits the endogenous function of a target RNA transcript.

[0118] As used herein, the terms "express" and "expression" refer to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end processing); and (3) translation of the RNA into a polypeptide or protein. In the context of a gene that encodes a protein product, terms such as "gene expression" are used interchangeably with terms such as "protein expression." Expression of a gene or protein of interest in a patient can be determined, for example, by detecting, in a sample obtained from the patient, an increase in the amount or concentration of mRNA encoding the corresponding protein (e.g., assessed using RNA detection procedures described herein or known in the art, such as quantitative polymerase chain reaction (qPCR) and RNA seq techniques), an increase in the amount or concentration of the corresponding protein (e.g., assessed using protein detection methods described herein or known in the art, such as enzyme-linked immunosorbent assay (ELISA), among others), and / or an increase in the activity of the corresponding protein (e.g., in the case of an enzyme, assessed using enzyme activity assays described herein or known in the art). As used herein, a cell is considered to "express" a gene or protein of interest if one or more, or all of the above events are detectable within the cell or in the medium in which the cell resides. For example, a gene or protein of interest is considered to be "expressed" by a cell, or population of cells, if it is possible to detect: (i) production of a corresponding RNA transcript, such as an mRNA template, by the cell, or population of cells (e.g., using the RNA detection procedures described herein); (ii) processing of the RNA transcript (e.g., splicing, editing, 5' capping, and / or 3' end processing, using the RNA detection procedures described herein); (iii) translation of the RNA template into a protein product (e.g., using the protein detection procedures described herein); and / or (iv) post-translational modification of the protein product (e.g., using the protein detection procedures described herein).

[0119] As used herein, the terms "target," "targeting," and "targeted" in the context of siRNA design refer to generating an antisense strand such that it anneals within a region within an mRNA transcript of interest in a manner that reduces translation of the mRNA into a protein product.

[0120] As used herein, the terms "chemically modified nucleotide," "nucleotide analog," "altered nucleotide," and "modified nucleotide" refer to non-standard nucleotides, including non-naturally occurring ribonucleotides or deoxyribonucleotides. Exemplary nucleotide analogs are modified at any position such that certain chemical properties of the nucleotide are altered while retaining the ability of the nucleotide analog to perform its intended function.

[0121] As used herein, the term "metabolically stabilized" refers to an RNA molecule that contains chemically modified ribonucleotides to reduce the metabolic rate of the RNA molecule administered to a subject. Exemplary modifications include 2'-hydroxy to 2'-O-methoxy or 2'-fluoro, and phosphodiester to phosphorothioate.

[0122] As used herein, the term "phosphorothioate" refers to a phosphate group of a nucleotide that is modified by replacing one or more of the oxygens of the phosphate group with sulfur.

[0123] As used herein, the terms "internucleoside" and "internucleotide" refer to the linkage between a nucleoside and a nucleotide, respectively.

[0124] As used herein, the term "antagomir" refers to a nucleic acid that can function as an inhibitor of miRNA activity.

[0125] As used herein, the term "gapmer" refers to a chimeric antisense nucleic acid that contains a central block of deoxynucleotide monomers of sufficient length to induce RNase H cleavage. The deoxynucleotide block is flanked by ribonucleotide monomers or ribonucleotide monomers containing modifications.

[0126] As used herein, the term "mixmer" refers to a nucleic acid composed of a mixture of locked nucleic acid (LNA) and DNA.

[0127] As used herein, the term "guide RNA" refers to a nucleic acid that has sequence complementarity to a specific sequence in a genome immediately upstream or one base pair upstream of a protospacer adjacent motif (PAM) sequence used in the CRISPR / Cas9 gene editing system. Alternatively, "guide RNA" may refer to a nucleic acid that has sequence complementarity (e.g., is antisense) to a specific messenger RNA (mRNA) sequence. In this context, a guide RNA may also have sequence complementarity to a "passenger RNA" sequence of equal or shorter length that is identical or substantially identical to the sequence of the mRNA to which the guide RNA hybridizes.

[0128] As used herein, the term "branched siRNA" refers to a compound that contains two or more double-stranded siRNA molecules that are covalently linked to each other.Branched siRNA molecules can be "bi-branched", also referred to herein as "di-siRNA", where this siRNA molecule comprises two siRNA molecules that are covalently linked to each other, for example, via a linker.Branched siRNA molecules can be "tri-branched", also referred to herein as "tri-siRNA", where this siRNA molecule comprises three siRNA molecules that are covalently linked to each other, for example, via a linker.Branched siRNA molecules can be "four-branched", also referred to herein as "tetra-siRNA", where this siRNA molecule comprises four siRNA molecules that are covalently linked to each other, for example, via a linker.

[0129] As used herein, the term "branch point moiety" refers to the chemical moiety of the branched siRNA structure of the present disclosure, which can be covalently attached to the 5'-end or 3'-end of the antisense or sense strand of siRNA molecule, and can support the attachment of additional single-stranded or double-stranded siRNA molecules.Non-limiting examples of branch point moieties suitable for use with the disclosed methods and compositions include, for example, phosphoramidite, tosylated solketal, 1,3-diaminopropanol, pentaerythritol, and any one of the branch point moieties described in US Patent No. 10,478,503.

[0130] The term "phosphate moiety" as used herein refers to a terminal phosphate group, including phosphate and modified phosphates. The phosphate moiety may be located at either terminus, but is preferred at the 5'-terminal nucleoside. In one aspect, the terminal phosphate has the formula -OP(=O)(OH)OH and is unmodified. In another aspect, the terminal phosphate is modified such that one or more of the O and OH groups are replaced with H, O, S, N(R'), or an alkyl where R' is H, an amino protecting group, or an unsubstituted or substituted alkyl. In some embodiments, the 5' and or 3' terminal groups can each independently comprise 1-3 phosphate moieties that are unmodified (diphosphate or triphosphate) or modified.

[0131] As used herein, the term "5' phosphorus stabilizing moiety" refers to a terminal phosphate group, including phosphate as well as modified phosphates (e.g., phosphorothioates, phosphodiesters, phosphonates). The phosphate moiety may be located at either terminus, but is preferred at the 5' terminal nucleoside. In one aspect, the terminal phosphate has the formula -OP(=O)(OH)OH and is unmodified. In another aspect, the terminal phosphate is modified such that one or more of the O and OH groups are replaced with H, O, S, N(R'), or an alkyl where R' is H, an amino protecting group, or an unsubstituted or substituted alkyl. In some embodiments, the 5' and or 3' terminal groups can each independently comprise one to three phosphate moieties that are unmodified (diphosphate or triphosphate) or modified.

[0132] The phosphate group of the nucleotide may also be modified, for example, by replacing one or more oxygens of the phosphate group with sulfur (e.g., phosphorothioates) or by making other substitutions that enable the nucleotide to perform its intended function, as described, for example, in Eckstein, Antisense Nucleic Acid Drug Dev. 10:117-21, 2000; Rusckowski et al., Antisense Nucleic Acid Drug Dev. 10:333-45, 2000; Stein, Antisense Nucleic Acid Drug Dev. 11:317-25, 2001; Vorobjev et al., Antisense Nucleic Acid Drug Dev. 11:77-85, 2001; and US 5,684,143.

[0133] As used herein, the term "complementary" refers to two nucleotides that form a canonical Watson-Crick base pair. For the avoidance of doubt, in the context of this disclosure, Watson-Crick base pairs include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs. In this context, proper Watson-Crick base pairs are referred to as "matches," while the respective unpaired and improperly paired nucleotides are referred to as "mismatches." Alignment for purposes of determining percent nucleic acid sequence complementarity can be accomplished in a variety of ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software.

[0134] "Percent sequence complementarity" to a reference polynucleotide sequence is defined as the percentage of nucleic acids in a candidate sequence that are complementary to nucleic acids in the reference polynucleotide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence complementarity. A given nucleotide is considered to be "complementary" to a reference nucleotide as described herein if the two nucleotides form a standard Watson-Crick base pair. For the avoidance of doubt, in the context of the present disclosure, Watson-Crick base pairs include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs. In this context, a proper Watson-Crick base pair is referred to as a "match," while each unpaired nucleotide and an improperly paired nucleotide are referred to as a "mismatch." Alignment for purposes of determining percent nucleic acid sequence complementarity can be accomplished in a variety of ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum complementarity over the entire length of the sequences being compared. By way of illustration, the percent sequence complementarity of a given nucleic acid sequence A to a given nucleic acid sequence B (which can alternatively be referred to as a given nucleic acid sequence A having a certain percent complementarity to a given nucleic acid sequence B) is calculated as follows: 100×(fraction X / Y) where X is the number of complementary base pairs in a program alignment of A and B (e.g., as performed by computer software such as BLAST) and Y is the total number of nucleic acids in B. It is understood that if the length of nucleic acid sequence A is not equal to the length of nucleic acid sequence B, then the percent sequence complementarity to B is not equal to the percent sequence complementarity of B to A. As used herein, a query nucleic acid sequence is considered to be "fully complementary" to a reference nucleic acid sequence if the query nucleic acid sequence has 100% sequence complementarity to the reference nucleic acid sequence.

[0135] "Percent sequence identity" with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to those in a reference polynucleotide or polypeptide sequence after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity. Alignment for the purpose of determining percent sequence identity of nucleic acids or amino acids can be achieved in a variety of ways that are within the capabilities of those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared. For example, percent sequence identity values ​​can be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence A to, with, or against a given nucleic acid or amino acid sequence B (which may alternatively be referred to as a given nucleic acid or amino acid sequence A having a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence B) is calculated as follows: 100×(fraction X / Y) where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in a programmatic alignment of A and B, and Y is the total number of nucleic acids in B. If the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, then the percent sequence identity of A to B will not be equal to the percent sequence identity of B to A.

[0136] The term "sufficiently complementary to hybridize" as used herein refers to a nucleic acid sequence or a portion thereof that does not have to be fully complementary (e.g., 100% complementary) to a target region or a nucleic acid sequence or a portion thereof, which has one or more nucleotide mismatches with the target region but can still hybridize to the target region under specified conditions. For example, a nucleic acid can be, for example, 95% complementary, 90% complementary, 85% complementary, 80% complementary, 75% complementary, 70% complementary, 65% complementary, 60% complementary, 55% complementary, 50% complementary, or less, but still form sufficient base pairs with the target to hybridize over its entire length.

[0137] Nucleic acid "hybridization" or "annealing" is achieved when one or more nucleoside residues within a polynucleotide base pair with one or more complementary nucleosides to form a stable duplex. Base pairing is usually caused by hydrogen bonding events. Hybridization includes Watson-Crick base pairs formed from natural and / or modified nucleobases. Hybridization may also include non-Watson-Crick base pairs, such as wobble base pairs (guanosine-uracil, hypoxanthine-uracil, hypoxanthine-adenine, and hypoxanthine-cytosine) and Hoogsteen base pairs. Nucleic acids do not need to be 100% complementary to undergo hybridization. For example, one nucleic acid can be, e.g., 95% complementary, 90% complementary, 85% complementary, 80% complementary, 75% complementary, 70% complementary, 65% complementary, 60% complementary, 55% complementary, 50% complementary, or less, to another nucleic acid, yet the two nucleic acids can form sufficient base pairs with each other to hybridize.

[0138] A "stable duplex" formed upon annealing / hybridization of one nucleic acid to another is a duplex structure that is not denatured by harsh washing. Exemplary harsh washing conditions are known in the art and include temperatures about 5°C below the melting temperatures of the individual strands of the duplex and low concentrations of monovalent salt, such as monovalent salt concentrations (e.g., NaCl concentrations) of less than 0.2M (0.2M, 0.19M, 0.18M, ​​0.17M, 0.16M, 0.15M, 0.14M, 0.13M, 0.12M, 0.11M, 0.1M, 0.09M, 0.08M, 0.07M, 0.06M, 0.05M, 0.04M, 0.03M, 0.02M, 0.01M, or lower).

[0139] The term "gene silencing" refers to the suppression of gene expression, for example, the endogenous gene expression of SCN9A, which can be mediated through the process of affecting transcription and / or the process of affecting post-transcriptional mechanisms.In some embodiments, gene silencing occurs when RNAi molecules initiate the inhibition or degradation of the mRNA transcribed from the gene of interest in a sequence-specific manner through RNA interference, thereby preventing the translation of the product of the gene.

[0140] As used herein, the term "overactive disease driver gene" refers to a gene with increased activity and / or expression that contributes to or causes a disease state in a subject (e.g., a human). The disease state may be caused or exacerbated by the overactive disease driver gene directly, or by an intermediary gene(s).

[0141] As used herein, the term "ethylene glycol chain" refers to a carbon chain having the formula ((CH2OH)2).

[0142] As used herein, "alkyl" refers to a saturated hydrocarbon group. Alkyl groups can be acyclic or cyclic and, if unsubstituted, contain only C and H. When naming an alkyl residue with a specific number of carbons, all geometric isomers with that number of carbons are intended to be encompassed and described. Thus, for example, "butyl" is meant to include n-butyl, sec-butyl, and iso-butyl. Examples of alkyl include ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. In some embodiments, alkyl can be substituted. Suitable substituents that can be introduced into alkyl groups include, for example, hydroxy, alkoxy, amino, alkylamino, and halo, among others.

[0143] As used herein, "alkenyl" refers to an acyclic or cyclic unsaturated hydrocarbon group having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C). Alkenyl groups, when unsubstituted, contain only C and H. When an alkenyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed and described. Thus, for example, "butenyl" is meant to include n-butenyl, sec-butenyl, and iso-butenyl. Examples of alkenyl include -CH=CH2, -CH2-CH=CH2, and -CH2-CH=CH-CH=CH2. In some embodiments, alkenyl can be substituted. Suitable substituents that can be introduced into alkenyl groups include, for example, hydroxy, alkoxy, amino, alkylamino, and halo, among others.

[0144] As used herein, "alkynyl" refers to an acyclic or cyclic unsaturated hydrocarbon group having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C). Alkynyl groups contain only C and H when unsubstituted. When an alkynyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed and described. Thus, for example, "pentynyl" is meant to include n-pentynyl, sec-pentynyl, and iso-pentynyl. Examples of alkynyl include -C≡CH and -C≡C-CH3. In some embodiments, alkynyl can be substituted. Suitable substituents that can be introduced into alkynyl groups include, for example, hydroxy, alkoxy, amino, alkylamino, and halo, among others.

[0145] As used herein, the term "phenyl" refers to a monocyclic arene having one hydrogen atom removed from a carbon atom of the ring. A phenyl group can be unsubstituted or substituted with one or more suitable substituents, which substitute for the H of the phenyl group.

[0146] As used herein, the term "benzyl" refers to the monovalent radical obtained when the hydrogen atom attached to the methyl group of toluene is removed. Benzyl generally has the formula phenyl-CH2-. A benzyl group can be unsubstituted or substituted with one or more suitable substituents. For example, a substituent may replace an H in the phenyl moiety and / or an H in the methylene (-CH2-) moiety.

[0147] As used herein, the term "amide" refers to an alkyl, alkenyl, alkynyl, or aromatic group bound to an aminocarbonyl functional group.

[0148] As used herein, the term "triazole" refers to a heterocyclic compound having the formula (C2H3N3) that has a five-membered ring of two carbons and three nitrogens, the positions of which can vary to give rise to multiple isomers.

[0149] As used herein, the term "end group" refers to the group at which a carbon chain or nucleic acid ends.

[0150] As used herein, "amino acid" refers to a molecule that contains an amine and a carboxyl functional group as well as a side chain characteristic of an amino acid.

[0151] In some embodiments, the amino acid is selected from the group of proteinogenic amino acids. In some embodiments, the amino acid is an L-amino acid or a D-amino acid. In some embodiments, the amino acid is a synthetic amino acid (e.g., a beta-amino acid).

[0152] As used herein, the term "lipophilic amino acid" refers to an amino acid that contains a hydrophobic moiety (eg, an alkyl chain or an aromatic ring).

[0153] As used herein, the term "delivery target" refers to an organ or part of the body to which it is desired to deliver a branched oligonucleotide composition.

[0154] As used herein, the term "between X and Y" is inclusive of values ​​of X and Y. For example, "between X and Y" refers to a range of values ​​between a value of X and a value of Y, as well as a value of X and a value of Y.

[0155] As used herein, the terms "subject" and "patient" are used interchangeably and refer to an organism, such as a mammal (e.g., a human) undergoing treatment for acute or chronic pain and / or containing a gain-of-function SCN9A variant gene. Examples of subjects and patients also include those diagnosed with pain disorders such as Gerhardt's disease, Mitchell's disease, Weir-Mitchell disease, and / or those who exhibit symptoms of erythromelalgia.

[0156] As used herein, the term "pain" includes all forms of chronic and acute pain, including neuropathic pain and nociceptive pain, among others, those cited herein.

[0157] As used herein, the term "SCN9A" refers to the gene encoding the Nav1.7 voltage-gated sodium ion channel protein, including the native SCN9A gene from any source. This term encompasses "full-length" unprocessed SCN9A and any form of SCN9A resulting from processing in cells. This term also encompasses naturally occurring variants of SCN9A, such as splice variants or allelic variants. The nucleic acid sequence of an exemplary SCN9A gene is shown in European Nucleotide Archive (ENA) Accession No. DQ857292.1. The amino acid sequence of an exemplary protein encoded by the SCN9A gene is shown in UNIPROT™ Accession No. Q15858.

[0158] As used herein, the terms "treat", "treated" and "treating" refer to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent, improve or slow (alleviate) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical outcome. Beneficial or desired clinical outcomes include, but are not limited to, a reduction in the patient's dependency on pain medication; relief of symptoms; a decrease in the severity of the condition, disorder or disease; stabilization (i.e., not worsening) of the condition, disorder or disease, a delay or slowing of the progression of the condition, disorder or disease; an improvement or remission (whether partial or complete) of the condition, disorder or disease, whether detectable or undetectable; an improvement in at least one measurable physical parameter, not necessarily recognized by the patient; or an improvement or amelioration of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without an excessive level of side effects. Treatment also includes prolonging survival compared to the expected survival if not receiving treatment.

[0159] As used herein, the terms "benefit" and "response" are used interchangeably in the context of a subject undergoing therapy for the treatment of, for example, acute pain, chronic pain, nociceptive pain, neuropathic pain, post-operative pain, inflammatory pain, erythromelalgia, primary erythromelalgia, secondary erythromelalgia, pain disorder, Gerhardt's disease, Mitchell's disease, or Weir-Mitchell disease. For example, clinical benefit in the context of a subject administered an siRNA molecule or siRNA composition of the present disclosure includes, but is not limited to, reduction in acute pain, chronic pain, dependence on analgesics, symptoms of erythromelalgia, wild-type SCN9A transcripts, mutant SCN9A transcripts, variant SCN9A transcripts, splice isoforms of SCN9A transcripts, and / or overexpression of SCN9A transcripts (relative to healthy subjects). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0160] The present disclosure provides compositions of small interfering RNA (siRNA) molecules having sequence homology with the sodium voltage-dependent channel alpha subunit 9 (SCN9A) gene, and methods for administering said siRNA molecules to the central nervous system of a subject. Furthermore, the siRNA molecules described herein may be configured as branched siRNA structures, such as biantennary, triantennary, and tetraantennary, and may further include specific patterns of chemical modifications (e.g., 2' ribose modifications or internucleoside linkage modifications) to improve resistance to nuclease enzymes, toxicity profiles, and physicochemical properties (e.g., thermal stability). Small interfering RNA molecules are short double-stranded RNA molecules. They can mediate RNA interference (RNAi) by degrading mRNAs with complementary nucleotide sequences, thus preventing the translation of target genes.

[0161] The siRNA molecules of the present disclosure may, for example, exhibit strong gene-specific suppression of SCN9A relative to other genes in the SCN family (e.g., SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN10A, and SCN11A). The siRNA sequences of the present disclosure also avoid gain-of-function variants of SCN9A that cause spontaneous pain (primary erythromelalgia), thereby maintaining the efficacy of the siRNA to provide analgesia in this genetically defined population.

[0162] The siRNA molecules of the present disclosure can be characterized by an antisense strand having a nucleic acid sequence that is complementary to a region within an SCN9A mRNA transcript having the nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152. The degree of complementarity of the antisense strand to the region of the SCN9A mRNA transcript can be sufficient for the antisense strand to anneal over the entire length of the region of the SCN9A mRNA transcript. For example, the antisense strand can have a nucleic acid sequence that is at least 60% complementary (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to a region of the SCN9A mRNA transcript.

[0163] In some embodiments, the siRNA molecule of the present disclosure is characterized by an antisense strand having a nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768, or a nucleic acid sequence that is at least 60% identical thereto. For example, the siRNA molecules of the present disclosure are characterized by an antisense strand having a nucleic acid sequence that is at least 60% identical (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768.

[0164] In some embodiments, the siRNA molecules of the present disclosure are characterized by a sense strand having a nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960, or a nucleic acid sequence at least 60% identical thereto. For example, the siRNA molecules of the present disclosure are characterized by a sense strand having a nucleic acid sequence that is at least 60% identical (e.g., 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960.

[0165] Exemplary siRNA molecules of the disclosure are shown below in Table 1. Table 1 summarizes the antisense strand, the sense strand, and the corresponding region of the SCN9A mRNA transcript targeted by each antisense strand. [Table 1-1] [Table 1-2]

Table 1-3

Table 1-4

Table 1-5

Table 1-6

Table 1-7

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

Table 1-31

Table 1-32

Table 1-33

Table 1-34

Table 1-35

[0166] siRNA structure The siRNA molecule of the present disclosure may be in the form of a single-stranded (ss) or double-stranded (ds) oligonucleotide structure. In some embodiments, the siRNA molecule may be a biantennary, triantennary, or tetraantennary molecule. In addition, the siRNA molecule of the present disclosure may contain one or more phosphodiester internucleoside linkages and / or their analogs, such as phosphorothioate internucleoside linkages. The siRNA molecule of the present disclosure may further contain chemically modified nucleosides with 2' sugar modifications.

[0167] The simplest siRNA consists of a ribonucleic acid containing a ss- or ds-structure, formed by a first strand (i.e., antisense strand) and, in the case of ds-siRNA, by a second strand (i.e., sense strand). The first strand comprises a stretch of consecutive nucleotides that is at least partially complementary to the target nucleic acid. The second strand also comprises a stretch of consecutive nucleotides, the second stretch being at least partially identical to the target nucleic acid. The first strand and said second strand can hybridize to each other to form a double-stranded structure. Hybridization typically occurs by Watson-Crick base pairing.

[0168] Depending on the sequence of the first and second strand, hybridization or base pairing is not necessarily complete or perfect, which means that the first and second strands are not 100% base paired due to mismatch.One or more mismatches can also exist in the double strand, without necessarily affecting the RNAi activity of siRNA.

[0169] The first strand comprises a stretch of contiguous nucleotides essentially complementary to the target nucleic acid. Typically, the target nucleic acid sequence is ss-RNA, preferably mRNA, according to the mode of action of the interfering ribonucleic acid. Such hybridization most likely occurs via Watson-Crick base pairing, but is not necessarily limited thereto. The extent to which the first strand has a complementary stretch of contiguous nucleotides to the target nucleic acid sequence can be 80% to 100%, for example, 80%, 85%, 90%, 95%, or 100% complementary.

[0170] The siRNA molecules described herein may employ modifications to the nucleobases, phosphate backbone, ribose core, 5' and 3' ends, and branching, where multiple strands of the siRNA may be covalently linked.

[0171] Length of the small interfering RNA molecule Within the scope of the present invention, any length known in the art and previously unknown can be employed for the present invention. As described herein, the potential length of the antisense strand of the siRNA molecule of the present disclosure is between 10 and 30 nucleotides (e.g., 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), between 15 and 25 nucleotides (e.g., 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides), or between 18 and 23 nucleotides (e.g., 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides). In some embodiments, the antisense strand is 20 nucleotides. In some embodiments, the antisense strand is 21 nucleotides. In some embodiments, the antisense strand is 22 nucleotides. In some embodiments, the antisense strand is 23 nucleotides. In some embodiments, the antisense strand is 24 nucleotides. In some embodiments, the antisense strand is 25 nucleotides. In some embodiments, the antisense strand is 26 nucleotides. In some embodiments, the antisense strand is 27 nucleotides. In some embodiments, the antisense strand is 28 nucleotides. In some embodiments, the antisense strand is 29 nucleotides. In some embodiments, the antisense strand is 30 nucleotides.

[0172] In some embodiments, the sense strand of the siRNA molecules of the present disclosure is between 12-30 nucleotides (e.g., 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides), or between 14-23 nucleotides (e.g., 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides). In some embodiments, the sense strand is 15 nucleotides in length. In some embodiments, the sense strand is 16 nucleotides in length. In some embodiments, the sense strand is 17 nucleotides in length. In some embodiments, the sense strand is 18 nucleotides in length. In some embodiments, the sense strand is 19 nucleotides in length. In some embodiments, the sense strand is 20 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length. In some embodiments, the sense strand is 22 nucleotides in length. In some embodiments, the sense strand is 23 nucleotides in length. In some embodiments, the sense strand is 24 nucleotides in length. In some embodiments, the sense strand is 25 nucleotides in length. In some embodiments, the sense strand is 26 nucleotides in length. In some embodiments, the sense strand is 27 nucleotides in length. In some embodiments, the sense strand is 28 nucleotides in length. In some embodiments, the sense strand is 29 nucleotides in length. In some embodiments, the sense strand is 30 nucleotides in length.

[0173] 2' sugar modification The present disclosure may include ss-siRNA and ds-siRNA molecular compositions that include at least one (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or more) nucleoside with a 2' sugar modification. Possible 2'-modifications include all possible orientations of OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl can be substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. In some embodiments, the modification includes a 2'-O-methyl (2'-O-Me) modification. Other potential sugar substituents include C1-C10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacokinetic properties of an oligonucleotide, and other substituents with similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (2'-O-CH2CH2OCH3, also known as 2'-O-(2-methoxyethyl) or 2'-MOE). In some embodiments, modifications include the group 2'-dimethylaminooxyethoxy, i.e., O(CH2)2ON(CH3)2, also known as 2'-DMAOE, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylamino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CHOCH2N(CH3). Other potential sugar substituents include, for example, aminopropoxy (-OCH2CH2CH2NH2), allyl (-CH2-CH=CH2), -O-allyl (-O-CH2-CH=CH2), and fluoro (F). The 2'-sugar substituent can be in the arabino (up) or ribo (down) position. In some embodiments, the 2'-arabino modification is 2'-F.Similar modifications may be made at other positions in the siRNA molecule, particularly the 3' position of the sugar in the 3' terminal nucleoside or 2'-5' linked oligonucleotides and the 5' position of the 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

[0174] Nucleobase Modifications The siRNA molecules of the present disclosure may also comprise nucleosides or other substitute or mimic monomer subunits that comprise nucleobases (often referred to in the art simply as "bases" or "heterocyclic base moieties").Nucleobases are other moieties that can be modified or substituted in a wide variety of ways, and such modified and / or substituted nucleobases can be in accordance with the present invention.As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases, also referred to herein as heterocyclic base moieties, include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3) uracil and cytosine, and other alkynyl derivatives of pyrimidine bases. Derivatives include 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaguanine and 3-deazaguanine. Nucleobases may also include those in which the purine or pyrimidine base is replaced by other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and 2-pyridone.Further nucleobases include those disclosed in US3,687,808, those disclosed in Kroschwitz, JI, ed. The Concise Encyclopedia of Polymer Science and Engineering, New York, John Wiley & Sons, 1990, pp. 858-859; those disclosed in Englisch et al., Angewandte Chemie, International Edition 30:613, 1991; and those disclosed in Sanghvi, YS, Chapter 16, Antisense Research and Applications, CRC Press, Gait, MJ ed., 1993, pp. 289-302. The siRNA molecules of the present disclosure can also contain polycyclic heterocyclic compounds instead of one or more heterocyclic base moieties. Many tricyclic heterocyclic compounds have been reported. These compounds are routinely used in antisense applications to increase the binding properties of modified strand to target strand.

[0175] Representative cytosine analogs that make three hydrogen bonds with guanosine in the second strand include 1,3-diazaphenoxazin-2-one (Kurchavov et al., Nucleosides and Nucleotides, 16:1837-46, 1997), 1,3-diazaphenothiazin-2-one (Lin et al. Am. Chem. Soc., 117:3873-4, 1995), and 6,7,8,9-tetrafluoro-1,3-diazaphenoxazin-2-one (Wang et al., Tetrahedron Lett., 39:8385-8, 1998). These base modifications incorporated into oligonucleotides have been shown to hybridize with complementary guanines, which in turn have been shown to hybridize with adenines through extended stacking interactions, improving the thermal stability of the helix (see also US10 / 155,920 and US10 / 013,295, both of which are incorporated herein by reference in their entireties). Further helix stabilizing properties have been observed when cytosine analogs / substitutes bear aminoethoxy moieties attached to a rigid 1,3-diazaphenoxazin-2-one scaffold (Lin et al., Am. Chem. Soc., 120:8531-2,1998).

[0176] Internucleoside bond modification Another variable in the design of the present invention is the internucleoside bond that constitutes the phosphate backbone of the siRNA molecule.Natural RNA phosphate backbone may be employed herein, but derivatives thereof may be used to improve the desired properties of the siRNA molecule.Of particular importance in this disclosure, but not limited to, is to protect part or the entire siRNA molecule from hydrolysis.One example of the modification that reduces the rate of hydrolysis is phosphorothioate.Any part or the entire backbone may contain phosphate substitution (e.g., phosphorothioate). For example, the internucleoside bond may be between 0 and 100% phosphorothioate, e.g., between 0 and 100%, 10 and 100%, 20 and 100%, 30 and 100%, 40 and 100%, 50 and 100%, 60 and 100%, 70 and 100%, 80 and 100%, 90 and 100%, 0 and 90%, 0 and 80%, 0 and 70%, 0 and 60%, 0 and 50%, 0 and 40%, 0 and 30%, 0 and 20%, 0 and 10%, 10 and 90%, 20 and 80%, 30 and 70%, 40% and 60%, 10 and 40%, 20 and 50%, 30 and 60%, 40 and 70%, 50 and 80%, or 60 and 90% phosphorothioate bond. Similarly, the internucleoside bond may be between 0 and 100% phosphodiester bonds, for example, between 0 and 100%, 10 and 100%, 20 and 100%, 30 and 100%, 40 and 100%, 50 and 100%, 60 and 100%, 70 and 100%, 80 and 100%, 90 and 100%, 0 and 90%, 0 and 80%, 0 and 70%, 0 and 60%, 0 and 50%, 0 and 40%, 0 and 30%, 0 and 20%, 0 and 10%, 10 and 90%, 20 and 80%, 30 and 70%, 40% and 60%, 10 and 40%, 20 and 50%, 30 and 60%, 40 and 70%, 50 and 80%, or 60 and 90% phosphodiester bonds.

[0177] Specific examples of some potential siRNA molecules useful in the present invention include oligonucleotides that contain modified, for example, non-naturally occurring internucleoside linkages.As defined herein, oligonucleotides with modified internucleoside linkages include internucleoside linkages that retain phosphorus atoms and internucleoside linkages that do not have phosphorus atoms.For the purposes of this specification and as sometimes referred to in the art, modified oligonucleotides that do not have phosphorus atoms in their internucleoside backbone can also be considered to be oligonucleosides.Preferred phosphorus-containing modified internucleoside linkages are phosphorothioate internucleoside linkages. In some embodiments, modified oligonucleotide backbones comprising a phosphorus atom therein include, for example, phosphorothioates, phosphodioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thinophosphoramidates, thinoalkyl phosphonates, thinoalkyl phosphotriesters, selenophosphates, boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs thereof, as well as those having inverted polarity where one or more internucleotide linkages are 3'-3', 5'-5', or 2'-2' linkages.Exemplary United States patents describing the preparation of phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; Same No. 5,321,131; Same No. 5,399,676; Same No. 5,405,939; Same No. 5,453,496; Same No. 5,455,233; Same No. 5,466,677; Same No. 5,476, No. 925; No. 5,519,126; No. 5,536,821; No. 5,541,316; No. 5,550,111; No. 5,563,253; No. 5,571,799; No. 5, No. 587,361; No. 5,625,050; No. 6,028,188; No. 6,124,445; No. 6,160,109; No. 6,169,170; No. 6,172,209 ; Same No. 6,239,265; Same No. 6,277,603; Same No. 6,326,199; Same No. 6,346,614; Same No. 6,444,423; Same No. 6,531,590; Same No. 6,534, Nos. 6,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Patent No. RE39464, the entire contents of each of which are incorporated herein by reference.

[0178] In some embodiments, modified oligonucleotide backbones that do not contain phosphorus atoms therein have backbones formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatom or heterocyclic internucleoside linkages. These include morpholino linkages (formed in part from the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; riboacetyl backbones; alkene-containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and other backbones with mixed N, O, S and CH2 moieties. Non-limiting examples of U.S. patents that teach the preparation of non-phosphorus scaffolds include, but are not limited to, U.S. Pat. Nos. 5,034,506, 5,166,315, 5,185,444, 5,214,134, 5,216,141, 5,235,033, 5,64,562, 5,264,564, 5,405,938, 5,434,257, 5,466,677, 5,470,967, 5,512,111, and 5,512,112. Nos. 5,489,677, 5,541,307, 5,561,225, 5,596,086, 5,602,240, 5,608,046, 5,610,289, 5,618,704, 5,623,070, 5,663,312, 5,633,360, 5,677,437, and 5,677,439, the entire contents of each of which are incorporated herein by reference.

[0179] Modification patterns of siRNA molecules The following section provides a set of exemplary scaffolds into which the siRNA molecules of the present disclosure can be incorporated.

[0180] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula I, where Formula I is in the 5'-3' direction: AB-(A') j -CP 2 -DP 1 -(C'-P 1 ) k -C' Formula I; where A is of the formula CP 1 -DP 1 Each A' is represented by the formula CP 2 -DP 2 B is represented by the formula CP 2 -DP 2 -DP 2 -DP 2 each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 4. In some embodiments, k is 4. In some embodiments, j is 4 and k is 4. The antisense is complementary (e.g., fully or partially complementary) to a target nucleic acid sequence.

[0181] In some embodiments, the antisense strand comprises a structure represented by Formula A1, which in the 5'-3' direction is: ASBSAOBOBOBOAOBOAOBOA-OBOAOBOAOBSASASASBSA Formula A1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0182] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula II, which in the 5'-3' direction is: AB-(A') j -CP 2 -DP 1 -(CP 1 ) k -C' Formula II; where A is of the formula CP 1 -DP 1 Each A' is represented by the formula CP 2 -DP 2 B is represented by the formula CP 2 -DP 2 -DP 2 -DP 2 each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 4. In some embodiments, k is 4. In some embodiments, j is 4 and k is 4. The antisense is complementary (e.g., fully or partially complementary) to a target nucleic acid sequence.

[0183] In some embodiments, the antisense strand comprises a structure represented by Formula A2, which, in the 5'-3' direction, is: ASBSAOBOBOBOAOBOAOBOA-OBOAAOBOAOBSASASASASA Formula A2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0184] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula III, which in the 5'-3' direction is: E-(A') m -F Formula III; In the formula, E is the formula (CP 1 )2; F is represented by the formula (CP 2 )3-DP 1 -CP 1 -C, (CP 2 )3-DP 2 -CP 2 -C, (CP 2 )3-DP 1 -CP 1 -D, or (CP 2 )3-DP 2 -CP 2 -D; A', C, D, P 1 , and P 2 is as defined in Formula I; and m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, m is 4. The sense strand is complementary (e.g., completely or partially complementary) to the antisense strand.

[0185] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S1, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBBSASA Formula S1; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0186] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S2, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOA Formula S2; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0187] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S3, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBSASB formula S3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0188] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S4, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OAOAOBOAOB Equation S4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0189] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula IV, where Formula IV is in the 5'-3' direction: A-(A') j -CP 2 -B-(CP 1 ) k -C' Formula IV; where A is of the formula CP 1 -DP 1 Each A' is represented by the formula CP 2 -DP 2 B is represented by the formula DP 1 -CP 1 -DP 1 each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 6. In some embodiments, k is 4. In some embodiments, j is 6 and k is 4. The antisense is complementary (e.g., fully or partially complementary) to a target nucleic acid.

[0190] In some embodiments, the antisense strand comprises a structure represented by Formula A3, which, in the 5'-3' direction, is: ASBSAOBOAOBOAOBOAOBOA-OBOAOBOAOBSASASASA formula A3; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0191] In some embodiments of the present disclosure, the siRNA of the present disclosure can have a sense strand represented by Formula V, where Formula V is, in the 5'-3' direction, the following: E-(A') m -CP 2 -F formula V; In the formula, E is the formula (CP 1 )2; F is represented by the formula DP 1 -CP 1 -C, D.P. 2 -CP 2 -C, D.P. 1 -CP 1 -D, or DP 2 -CP 2 -D; A', C, D, P 1 , and P 2 is as defined in formula IV; and m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, m is 5. The sense strand is complementary (e.g., fully or partially complementary) to the antisense strand.

[0192] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S5, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASA Formula S5; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0193] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S6, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOA Formula S6; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage. In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S7, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBSASB Formula S7; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0194] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S8, which in the 5'-3' direction is: ASASAOBOAOBOAOBOAOBOA-OBOAOBOAOB formula S8; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0195] In some embodiments of the present disclosure, the siRNA may contain an antisense strand that includes a region represented by Formula VI, where Formula VI is in the 5'-3' direction: A.B. j -EB k -EFG l -DP 1 -C' Formula VI; where A is of the formula CP 1 -DP1 Each B is represented by the formula CP 2 each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; each E is represented by the formula DP 2 -CP 2 F is represented by the formula DP 1 -CP 1 Each G is represented by the formula CP 1 Each P 1 is a phosphorothioate internucleoside linkage; each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); k is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and l is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, j is 3. In some embodiments, k is 6. In some embodiments, l is 2. In some embodiments, j is 3, k is 6, and l is 2. The antisense strand is complementary (e.g., fully or partially complementary) to a target nucleic acid.

[0196] In some embodiments, the antisense strand comprises a structure represented by Formula A4, which, in the 5'-3' direction, is: ASBSAOAOAOBOAOAOAOAOA-OAOAOBOAOBSASASASBSA formula A4; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0197] In some embodiments of the present disclosure, the siRNA may contain a sense strand that includes a region represented by Formula VII, which in the 5'-3' direction is: HBm -I n -A'-B o -HC Formula VII; where A' is a compound of the formula CP 2 -DP 2 Each H is represented by the formula (CP 1 )2; each I is represented by the formula (DP 2 ) are represented by B, C, D, P 1 , and P 2 is as defined in formula VI; m is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); n is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7); and o is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). In some embodiments, m is 3. In some embodiments, n is 3. In some embodiments, o is 3. In some embodiments, m is 3, n is 3, and o is 3. The sense strand is complementary (e.g., fully or partially complementary) to the antisense strand.

[0198] In some embodiments of the present disclosure, the sense strand comprises a structure represented by formula S9, which in the 5'-3' direction is: ASASAOAOAOBOBOBOBOAOBOA-OAOAOAASASA Formula S9; wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

[0199] In some embodiments of the present disclosure, the siRNA may contain an antisense strand comprising a region represented by Formula VIII: Z-((AP-) n (BP-) m ) q ; Formula VIII wherein Z is a 5' phosphorus stabilizing moiety; each A is a 2'-O-methyl (2'-O-Me) ribonucleoside; each B is a 2'-fluoro-ribonucleoside; each P is independently an internucleoside linkage selected from a phosphodiester linkage and a phosphorothioate linkage; n is an integer from 1 to 5 (e.g., 1, 2, 3, 4, or 5); m is an integer from 1 to 5 (e.g., 1, 2, 3, 4, or 5); and q is an integer between 1 and 30 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30).

[0200] Methods for synthesizing siRNA The siRNA molecules of the present disclosure can be synthesized by standard methods known in the art, for example, by use of an automated DNA synthesizer such as those commercially available from Biosearch, Applied Biosystems, Inc., as discussed further below.

[0201] siRNA agent can be prepared by using liquid phase organic synthesis or solid phase organic synthesis or both.Organic synthesis has the advantage that it is easy to prepare the oligonucleotide that contains non-natural nucleotide or modified nucleotide.The siRNA molecule of the present disclosure can be prepared by using liquid phase organic synthesis or solid phase organic synthesis or both.

[0202] Furthermore, it is contemplated that any siRNA agent disclosed herein can be further optimized by systematically adding or removing linked nucleosides to generate longer or shorter sequences.Furthermore, such optimized sequences can be adjusted by introducing modified nucleosides and / or modified internucleoside linkages, as described herein or known in the art, including, for example, alternative nucleosides, alternative sugar moieties, and / or alternative internucleoside linkages, as known in the art and / or discussed herein, to further optimize the molecule (e.g., increase serum stability or circulating half-life, increase thermal stability, enhance transmembrane delivery, and / or target to specific locations or cell types).

[0203] 5' phosphorus stabilizing moiety To further protect the siRNA molecule of the present disclosure from degradation, 5'-phosphorus stabilizing moiety can be adopted. 5'-phosphorus stabilizing moiety replaces 5'-phosphate to prevent hydrolysis of phosphate. Hydrolysis of 5'-phosphate prevents binding to RISC, which is a necessary step of gene silencing. Any substitution of phosphate that does not prevent binding to RISC is contemplated in the present disclosure. In some embodiments, the substitution of 5'-phosphate is also stable to hydrolysis in vivo. Each strand of siRNA molecule may independently and optionally adopt any suitable 5'-phosphorus stabilizing moiety. [ka]

[0204] Some exemplary end caps are illustrated in Formulae IX-XVI. Nuc in Formulae IX-XVI represents a nucleobase or nucleobase derivative or substitute as described herein. X in Formulae IX-XVI represents a 2'-modification as described herein. Some embodiments employ hydroxy as in Formula IX, phosphate as in Formula X, vinyl phosphonate as in Formulae XI and XIV, 5'-methyl substituted phosphate as in Formulae XII, XIII, and XVI, methylene phosphonate as in Formula XV, or vinyl 5'-vinyl phosphonate as shown in Formula XI as the 5'-phosphorus stabilizing moiety.

[0205] hydrophobic part The present disclosure further provides siRNA molecules with one or more hydrophobic moieties attached.Hydrophobic moieties can be covalently attached to the 5'-end or 3'-end of the siRNA molecules of the present disclosure.Non-limiting examples of the hydrophobic moieties suitable for use with the siRNA molecules of the present disclosure can include cholesterol, vitamin D, tocopherol, phosphatidylcholine (PC), docohexaenoic acid, docosanoic acid, PC-docosanoic acid, eicosapentaenoic acid, lithocholic acid, or any combination of the aforementioned hydrophobic moieties and PC.

[0206] siRNA branching The siRNA molecules of the present disclosure may be branched. For example, the siRNA molecules of the present disclosure may have one of several branching patterns as described herein.

[0207] According to the present disclosure, the siRNA molecule disclosed herein may be a branched siRNA molecule. The siRNA molecule may be unbranched or bi-, tri- or tetra-branched, connected via a linker. Each main branch may be further branched to allow 2, 3, 4, 5, 6, 7 or 8 separate RNA single or double strands. The branching points on the linker may originate from the same atom or may originate from separate atoms along the linker. Some exemplary embodiments are listed in Table 2. [Table 2]

[0208] In some embodiments, the siRNA molecule is a branched siRNA molecule. In some embodiments, the branched siRNA molecule is biantennary, triantennary, or tetraantennary. In some embodiments, the biantennary siRNA molecule is represented by any one of formulas XVII-XIX, where each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety (e.g., phosphoramidite, tosylated solketal, 1,3-diaminopropanol, pentaerythritol, or any one of the branch point moieties described in US10,478,503).

[0209] In some embodiments, the three-branched siRNA molecule is represented by any one of formulas XX-XXIII, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

[0210] In some embodiments, the four-branched siRNA molecule is represented by any one of Formulas XXIV-XXVIII, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

[0211] Linker The multiple strands of the siRNA described herein may be covalently linked by a linker. This branching effect, among other things, improves cell permeability, allowing better access to cells (e.g., neurons or glial cells) in the CNS. Any linker moiety that is not incompatible with the siRNA of the present invention may be employed. Linkers include ethylene glycol chains of 2-10 subunits (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 subunits), alkyl chains, carbohydrate chains, block copolymers, peptides, RNA, DNA, and others. In some embodiments, the carbon or oxygen atoms of the linker are optionally replaced with nitrogen atoms, have hydroxyl substituents, or have oxo substituents. In some embodiments, the linker is a polyethylene glycol (PEG) linker. PEG linkers suitable for use in the disclosed compositions and methods include linear or non-linear PEG linkers. Examples of non-linear PEG linkers include branched PEG, linear forked PEG, or branched forked PEG.

[0212] PEG linkers of various weights may be used in the disclosed compositions and methods. For example, the PEG linker may have a weight between 5 and 500 daltons. In some embodiments, a PEG linker having a weight between 500 and 1,000 daltons may be used. In some embodiments, a PEG linker having a weight between 1,000 and 10,000 daltons may be used. In some embodiments, a PEG linker having a weight between 200 and 20,000 daltons may be used. In some embodiments, the linker is covalently attached to the sense strand of the siRNA. In some embodiments, the linker is covalently attached to the antisense strand of the siRNA. In some embodiments, the PEG linker is a triethylene glycol (TrEG) linker. In some embodiments, the PEG linker is a tetraethylene linker (TEG).

[0213] In some embodiments, the linker is an alkyl chain linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is an RNA linker. In some embodiments, the linker is a DNA linker.

[0214] The linker may covalently link two, three, four, or five unique siRNA strands. The linker may be covalently linked to any portion of the siRNA oligomer. In some embodiments, the linker is attached to the 3' end of the nucleoside of each siRNA strand. In some embodiments, the linker is attached to the 5' end of the nucleoside of each siRNA strand. In some embodiments, the linker is attached to the nucleoside of the siRNA strand (e.g., the sense strand or the antisense strand) via a covalent bond forming moiety. In some embodiments, the covalent bond forming moiety is selected from the group consisting of alkyl, ester, amide, carbonate, carbamate, triazole, urea, formacetal, phosphonate, phosphate, and phosphate derivatives (e.g., phosphorothioate, phosphoramidate, etc.).

[0215] In some embodiments, the linker has the structure of formula L1. [ka]

[0216] In some embodiments, the linker has the structure of formula L2: [ka]

[0217] In some embodiments, the linker has the structure of formula L3. [ka]

[0218] In some embodiments, the linker has the structure of formula L4. [ka]

[0219] In some embodiments, the linker has the structure of formula L5. [ka]

[0220] In some embodiments, the linker has the structure of formula L6. [ka]

[0221] In some embodiments, the linker has the structure of formula L7. [ka]

[0222] In some embodiments, the linker has the structure of formula L8. [ka]

[0223] In some embodiments, the linker has the structure of formula L9. [ka]

[0224] In some embodiments, the selection of a linker for use in one or more of the branched siRNA molecules disclosed herein may be based on the hydrophobicity of the linker, for example, to achieve a desired hydrophobicity for one or more of the branched siRNA molecules of the present disclosure.For example, a linker containing an alkyl chain may be used to increase the hydrophobicity of the branched siRNA molecule compared to a branched siRNA molecule having a less hydrophobic or hydrophilic linker.

[0225] The siRNA agents disclosed herein can be synthesized and / or modified by methods well established in the art, such as those described in Beaucage, SL et al. (eds.), Current Protocols in Nucleic Acid Chemistry, John Wiley & Sons, Inc., New York, NY, 2000, which is incorporated herein by reference.

[0226] Treatment method The SCN9A-targeting siRNA molecules of the present disclosure can be delivered to a subject, for example, as an analgesic agent effective against multiple forms of acute or chronic pain (e.g., nociceptive pain or neuropathic pain). Additionally, the siRNA molecules of the present disclosure can be delivered to a subject with a gain-of-function variant of the SCN9A gene (e.g., primary erythromelalgia), where siRNA-mediated gene silencing of the SCN9A variant gene reduces the expression level of the SCN9A transcript, thereby reducing the level of pain experienced by the subject and / or alleviating symptoms of pain disorders such as Gerhardt's disease, Mitchell's disease, or Weir-Mitchell disease.

[0227] The present disclosure provides a method of treating a subject by SCN9A gene silencing with one or more small interfering RNA (siRNA) molecules described herein. Gene silencing can be performed in a subject to silence wild-type SCN9A transcripts, mutant SCN9A transcripts, splice isoforms of SCN9A transcripts, and / or overexpressed SCN9A transcripts thereof, compared to healthy subjects. The method can include delivering the siRNA molecule of the present disclosure or a pharmaceutical composition containing the same to the CNS or neurons of a subject (e.g., a human) by any suitable route of administration (e.g., intrathecal injection, direct injection into a specific nerve or ganglion (ganglia), such as the trigeminal ganglion or dorsal root ganglion, or intracisternal injection by catheter insertion). The active compound can be administered at any suitable dose. The actual dosage of the composition of the present disclosure administered to a patient can be determined by physical and physiological factors, such as body weight, severity of the condition, prior or concurrent therapeutic interventions, idiopathic disease of the patient, and route of administration. Depending on the dosage and route of administration, the preferred dosage and / or the number of times of administration of the effective amount may vary depending on the subject's response.The practitioner responsible for administration will in any case determine the concentration of active ingredient(s) in the composition and the appropriate dose(s) for each subject.Administration can be performed any suitable number of times per day for the period required.The subject may be an adult or pediatric human, with or without co-morbidities.

[0228] Selecting a target The subject that can be treated with the small interfering RNA (siRNA) molecules disclosed herein is a subject in need of treatment for chronic, persistent, or acute pain symptoms. Such pain symptoms can be neuropathic or nociceptive in nature. Furthermore, the subject in need of pain treatment can be characterized as having spontaneous pain (e.g., primary erythromelalgia or secondary erythromelalgia) or can be diagnosed with a pain disorder (e.g., Gerhardt's disease, Mitchell's disease, or Weir-Mitchell disease). The subject that can be treated with the siRNA molecules disclosed herein can include, for example, humans, monkeys, rats, mice, pigs, and other mammals that contain at least one homologous copy of the SCN9A gene. The subject can be an adult or pediatric human, with or without a co-morbidity.

[0229] Pharmaceutical Compositions The siRNA molecule of the present disclosure can be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration in vivo.Therefore, the present disclosure provides pharmaceutical compositions that contain the siRNA molecule of the present disclosure mixed with suitable diluent, carrier or excipient.The siRNA molecule can be directly administered to the CNS or affected tissue or neuron of a subject, for example, by intraventricular injection, intrastriatal injection, intrathecal injection, intracisternal injection by catheter insertion, intraparenchymal injection, direct injection into specific nerve or ganglion (ganglia) (for example, trigeminal ganglion or dorsal root ganglion), intravenous injection, subcutaneous injection, or intramuscular injection.

[0230] Procedures and ingredients for selecting and preparing suitable formulations are described, for example, in Remington, JP The Science and Practice of Pharmacy, Easton, PA. Mack Publishers, 2012, 22nd ed. and The Science and Practice of Pharmacy, Easton, PA. Mack Publishers, 2012, 22 nded. and the National Formulary, United States Pharmacopeial, 2015, USP 38 NF 33).

[0231] Under normal storage and use conditions, the pharmaceutical compositions may contain preservatives, for example, to prevent the growth of microorganisms. The pharmaceutical compositions may include sterile aqueous solutions, sterile dispersions, or powders, for example, for the extemporaneous preparation of sterile solutions or dispersions. In all cases, the forms can be sterilized using techniques known in the art and can be fluidized to the extent that they can be easily administered to the subject in need of treatment.

[0232] Pharmaceutical compositions may be administered to a subject, e.g., a human subject, alone or in combination with pharma- ceutically acceptable carriers, as provided herein, the proportions of which may be determined by the solubility and / or chemical properties of the compound, the chosen route of administration, and standard pharmaceutical practice.

[0233] Dosing regimen A physician of ordinary skill in the art can easily determine the effective amount of siRNA molecule to be administered to a mammalian subject (e.g., human) in need thereof.For example, a physician can begin to prescribe a dose of one of the siRNA molecules of the present disclosure at a level lower than that required to achieve a desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Alternatively, a physician can begin a treatment regimen by administering one of the siRNA molecules of the present disclosure at a high dose, and then administer progressively lower doses until the minimum dosage at which a therapeutic effect (e.g., reduction in expression of a target gene sequence) is reached.In general, a suitable daily dose of one of the siRNA molecules of the present disclosure is the amount of the lowest dose of the siRNA molecule that is effective to produce a therapeutic effect. The ss- or ds-siRNA molecules of the present disclosure can be administered by injection, for example, intrathecal, intracerebroventricular, intracisternal injection by catheter insertion, intraparenchymal, direct injection into a specific nerve or ganglion (ganglia) (e.g., trigeminal ganglion or dorsal root ganglion), intravenous, subcutaneous, or intramuscular injection. The daily dose of the therapeutic composition of the siRNA molecules of the present disclosure can be administered as a single dose, or as two, three, four, five, six, or more doses administered separately at appropriate intervals throughout the day, week, month, or year, optionally in a unit dosage form. The siRNA molecules of the present disclosure can be administered alone, but can also be administered in pharmaceutical formulations in combination with excipients, carriers, and optionally additional therapeutic agents.

[0234] Route of administration The disclosed method contemplates any route of administration tolerated by the therapeutic composition. Some embodiments of the method include by intrathecal injection or intracisternal injection via catheter insertion. Some embodiments of the method include direct injection into a specific nerve or ganglion (ganglia) (e.g., the trigeminal ganglion or dorsal root ganglion).

[0235] Intrathecal injection is direct injection into the spinal column or subarachnoid space.By direct injection into the CSF of the spinal column, the siRNA molecules of the present disclosure have direct access to cells (e.g., neurons and glial cells) in the spinal column, and have a route to bypass the blood-brain barrier to access cells in the brain, or to access the cell bodies of neurons outside the blood-brain barrier.

[0236] Intracerebroventricular (ICV) injection is a method of injection directly into the CSF in the ventricles of the brain. Like intrathecal injection, ICV is an injection method that bypasses the blood-brain barrier. The use of ICV offers the advantage of accessing cells in the brain and spinal column without the risk of the therapeutic agent being degraded in the blood.

[0237] Intrastriatal injection is a direct injection into the striatum (or corpus striatum), a subcortical basal ganglia region of the brain. Injection into the striatum bypasses the blood-brain barrier, avoiding the pharmacokinetic challenges of injection into the bloodstream, and allows direct access to brain cells.

[0238] Intraparenchymal administration is direct injection into the parenchyma (e.g., brain parenchyma). Injection into the brain parenchyma allows for direct injection into the brain region affected by the disease or disorder, bypassing the blood-brain barrier.

[0239] Intracisternal injection by catheterization is a direct injection into the cisterna magna, an area of ​​the brain located between the cerebellum and the dorsal aspect of the medulla oblongata. Injection into the cisterna magna provides more direct delivery to cells in the cerebellum, brainstem, and spinal cord.

[0240] In some embodiments of the methods described herein, the therapeutic composition can be delivered to the subject by systemic administration, for example, intravenous, intramuscular, or subcutaneous administration.

[0241] Intravenous (IV) injection is a method of injection directly into the bloodstream of a subject. IV administration may be in the form of a bolus dose, by continuous infusion, or any other method permitted by the therapeutic composition.

[0242] An intramuscular (IM) injection is an injection into a muscle of the subject, such as the deltoid or gluteal muscle. IM may allow for rapid absorption of the therapeutic composition.

[0243] Subcutaneous injections are injections into the subcutaneous tissue. Absorption of compositions delivered subcutaneously may be slower than IV or IM injections, which may be beneficial for compositions that require continuous absorption. EXAMPLES

[0244] The following examples are presented to provide one of ordinary skill in the art with an illustration of how the compositions and methods described herein can be used, made, and evaluated, and are intended to be purely illustrative of the disclosure and are not intended to limit the scope of what the inventors regard as their disclosure.

[0245] Example 1. Knockdown of SCN9A with siRNA molecules of the present disclosure The activity of the SCN9A-targeting siRNA molecules of the present disclosure was screened. G402 cells were cultured in the presence of the siRNA molecules of the present disclosure at a concentration of either 2 μM or 0.5 μM. After 72 hours, the cells were lysed and the mRNA levels of SCN9A and housekeeping gene (GAPDH) were evaluated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) using standard reagents and Applied Biosystems TaqMan assay. The results are shown in Table 3 below as the percentage of remaining SCN9A mRNA (in % SCN9A mRNA) corrected for changes in expression by housekeeping genes compared to untreated control cells in the same assay. STDEV=standard deviation; ND=not determined. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12]

[0246] Example 2. Determination of IC50 potency of siRNA molecules of the present disclosure For compound potency analysis, G402 cells were actively transfected with SCN9A-targeting siRNA at concentrations ranging from 1 fM to 100 nM. SCN9A mRNA expression was assessed at 72 hours using RT-qPCR as described in Example 1 above, and the IC50 of each compound was calculated. Two siRNA molecules were tested in this assay: (1) an siRNA molecule with an antisense strand of SEQ ID NO:688 and a sense strand of SEQ ID NO:880, with an IC50 of 0.0334 nM, and (2) an siRNA molecule with an antisense strand of SEQ ID NO:586 and a sense strand of SEQ ID NO:778, with an IC50 of 0.0166 nM. The IC50 curves are shown in Figure 1.

[0247] Example 3. Generation of SCN9A-targeting siRNA molecules Small interfering RNA (siRNA) of the present disclosure can be synthesized by standard methods known in the art, for example, by use of an automated DNA synthesizer such as those commercially available from Biosearch, Applied Biosystems, Inc., as discussed further below.

[0248] siRNA agents can be prepared using liquid-phase organic synthesis or solid-phase organic synthesis, or both. Organic synthesis has the advantage that oligonucleotides containing non-natural or modified nucleotides can be easily prepared. Specific examples of siRNA molecules are shown in Table 1 above, with the nucleotide sequences of sense and antisense strands, and the sodium voltage-dependent channel alpha subunit 9 (SCN9A) mRNA target sequence. Those skilled in the art will understand that antisense (AS) strands can be annealed to corresponding sense (S) strands to generate ds-siRNA molecules. Alternatively, those skilled in the art can use only antisense strands to induce ss-siRNA molecules.

[0249] Example 4. Optimization of SCN9A-targeting siRNA molecules In the case of the siRNA agents disclosed herein, it is contemplated that modifications to siRNA can further optimize the efficacy or biophysical properties of the molecule (e.g., increasing serum stability or circulatory half-life, increasing thermal stability, enhancing transmembrane delivery, and / or targeting to a specific location or cell type). Such optimization can be achieved by systematically adding or removing linked nucleosides to generate longer or shorter sequences for any siRNA agent disclosed herein. Further optimization of siRNA can include, for example, the incorporation of one or more alternative nucleosides, alternative 2' sugar moieties, and / or alternative internucleoside linkages. Furthermore, such optimized siRNA molecules can include the introduction of hydrophobic and / or stabilizing moieties at the 5' and / or 3' ends.

[0250] Optimizing siRNA with alternative nucleosides Optimization of the siRNA molecules of the present disclosure may include one or more of the following nucleoside modifications: 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3) uracil and cytosine, and other alkynyl derivatives of pyrimidine bases. , 6-azo-uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine, and / or 7-deazaguanine and 3-deazaguanine. siRNA molecules may also include nucleobases in which the purine or pyrimidine base is replaced by other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and / or 2-pyridone. Further optimization of the siRNA molecules of the present disclosure may include nucleobases disclosed in US 3,687,808; Kroschwitz, JI, ed. The Concise Encyclopedia of Polymer Science and Engineering, New York, John Wiley & Sons, 1990, pp. 858-859; Englisch et al., Angewandte Chemie, International Edition 30:613, 1991; and Sanghvi, YS, Chapter 16, Antisense Research and Applications, CRC Press, Gait, MJ ed., 1993, pp. 289-302.

[0251] Optimization of siRNAs by alternative sugar modifications Optimization of the siRNA molecules of the present disclosure may include one or more of the following 2' sugar modifications: 2'-O-methyl (2'-O-Me), 2'-methoxyethoxy (also known as 2'-O-CH2CHOCH3, 2'-O-(2-methoxyethyl) or 2'-MOE), 2'-dimethylaminooxyethoxy, i.e., O(CH2)2ON(CH3)2 group, also known as 2'-DMAOE, and / or 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylamino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CHOCH2N(CH3)2. Other possible 2' modifications that can optimize the siRNA molecules of the present disclosure include OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or all possible orientations of O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl include all possible orientations of substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. Other potential sugar substituents include, for example, aminopropoxy (-OCH2CH2CH2NH2), allyl (-CH2-CH=CH2), -O-allyl (-O-CH2-CH=CH2), and fluoro (F). The 2'-sugar substituent can be in the arabino (up) or ribo (down) position. In some embodiments, the 2'-arabino modification is 2'-F. Similar modifications may be made at other positions in the siRNA molecule, particularly the 3' position of the sugar in the 3' terminal nucleoside or 2'-5' linked oligonucleotides and the 5' position of the 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

[0252] Optimization of siRNAs with alternative internucleoside linkages Optimization of the siRNA molecules of the present disclosure may include one or more of the following internucleoside modifications: phosphorothioates, phosphodioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thinophosphoramidates, thinoalkyl phosphonates, thinoalkyl phosphotriesters, selenophosphates, boranophosphates with normal 3'-5' linkages, 2'-5' linked analogs of these, as well as those with inverted polarity where one or more internucleotide linkages are 3'-3', 5'-5', or 2'-2' linkages.

[0253] Optimization of siRNA using hydrophobic moieties The optimization of the siRNA molecule of the present disclosure may include covalently linked hydrophobic moiety at 5'-end or 3'-end.The non-limiting examples of the hydrophobic moiety suitable for use with the siRNA molecule of the present disclosure may include cholesterol, vitamin D, tocopherol, phosphatidylcholine (PC), docohexaenoic acid, docosanoic acid, PC-docosanoic acid, eicosapentaenoic acid, lithocholic acid, or any combination of the above hydrophobic moiety and PC.

[0254] Optimization of siRNA using stabilizing molecules The optimization of the siRNA molecules of the present disclosure may include a 5'-phosphorus stabilizing moiety that protects the siRNA molecules from degradation. The 5'-phosphorus stabilizing moiety replaces the 5'-phosphate to prevent hydrolysis of the phosphate. Hydrolysis of the 5'-phosphate prevents binding to RISC, which is a necessary step of gene silencing. Any substitution of the phosphate that does not prevent binding to RISC is contemplated in the present disclosure. In some embodiments, the substitution of the 5'-phosphate is also stable to hydrolysis in vivo. Each siRNA strand may independently and optionally employ any suitable 5'-phosphorus stabilizing moiety. Non-limiting examples of 5' stabilizing moieties suitable for use with the siRNA molecules of the present disclosure include those shown in formulas IX to XVI above.

[0255] Optimization of siRNA using branched siRNA The optimization of the siRNA molecule of the present disclosure may include the incorporation of branching patterns, such as bi-branched, tri-branched, or tetra-branched siRNAs connected via linker.Each main branch may be further branched to allow 2, 3, 4, 5, 6, 7, or 8 separate RNA single strands or double strands.The branching points on the linker may originate from the same atom, or may originate from separate atoms along the linker.Some exemplary embodiments are listed in Table 2 above.

[0256] The siRNA compositions of the present disclosure can be optimized to be in the form of a biantennary siRNA molecule represented by any one of formulas XVII-XIX, a triantennary siRNA molecule represented by any one of formulas XX-XXIII, and / or a tetraantennary siRNA molecule represented by any one of formulas XXIV-XXVIII, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety (e.g., a phosphoramidite, a tosylated solketal, 1,3-diaminopropanol, pentaerythritol, or any one of the branch point moieties described in US 10,478,503).

[0257] Example 5. Preparation and administration of SCN9A-targeting siRNA molecules The siRNA molecule of the present disclosure can be formulated into a pharmaceutical composition for administration to a subject in a biologically compatible form suitable for administration in vivo.For example, the siRNA molecule of the present disclosure can be administered with a suitable diluent, carrier, or excipient, and can further include a preservative, for example, to prevent microbial growth.The procedure and ingredients for selecting and preparing a suitable formulation can be found, for example, in Remington, JP The Science and Practice of Pharmacy, Easton, PA. Mack Publishers, 2012, 22 nd ed. and the National Formulary, United States Pharmacopeial, 2015, USP 38 NF 33).

[0258] The method of the present disclosure contemplates the administration route to the CNS or neurons of the subject that is tolerated by the siRNA composition of the present disclosure.Non-limiting examples of siRNA injection to the CNS or neurons include intrathecal injection, intracisternal injection by catheter insertion, or direct injection into specific nerve or ganglion (ganglia) (e.g., trigeminal ganglion or dorsal root ganglion).A physician of ordinary skill in the art can easily determine effective administration route.

[0259] Example 6. Methods for the treatment of pain using SCN9A-targeted siRNA molecules A subject in need of treatment for chronic, persistent, or acute pain symptoms, such as pain that is nociceptive or neuropathic in nature, is treated with administration of the siRNA molecule or siRNA composition of the present disclosure, formulated as a salt, at a frequency determined by the physician. A physician of ordinary skill in the art can easily determine the effective amount of siRNA molecule to administer to a mammalian subject (e.g., human) in need thereof. For example, a physician can begin prescribing a dose of one of the siRNA molecules of the present disclosure at a level lower than that required to achieve a desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Alternatively, a physician can begin a treatment regimen by administering one of the siRNA molecules of the present disclosure at a high dose, and then administer progressively lower doses until a therapeutic effect (e.g., reduction in the expression of SCN9A mRNA) is achieved. In general, a suitable daily dose of one of the siRNA molecules of the present disclosure is the amount of the lowest dose effective to produce a therapeutic effect. The ss- or ds-siRNA molecules of the present disclosure can be administered by injection, for example, intrathecal injection, direct injection into a specific nerve or ganglion (ganglia) (e.g., trigeminal ganglion or dorsal root ganglion), or intracisternal injection by catheter insertion. A daily dose of a therapeutic composition of one of the siRNA molecules of the present disclosure may be administered as a single dose, or as two, three, four, five, six or more doses administered separately at appropriate intervals throughout the day, week, month, or year, optionally in a unit dosage form. Any of the siRNA molecules of the present disclosure can be administered alone, but can also be administered in a pharmaceutical formulation in combination with an excipient, carrier, and optionally additional therapeutic agents. The dosage and frequency are determined based on the height, weight, age, sex, and other disorders of the subject.

[0260] The siRNA molecule of the present disclosure is selected by a physician considering its compatibility with a subject.Can select single-stranded or double-stranded siRNA molecules (e.g., unbranched siRNA, bibranched siRNA, tri-branched siRNA, tetra-branched siRNA).Selected siRNA molecule can have antisense strand and sense strand with optimal sequence and RNA modification for patient (e.g., natural and non-natural internucleoside bond, modified sugar, 5' phosphorus stabilizing portion, hydrophobic portion, and / or branched structure).

[0261] The siRNA molecules are delivered by the route best suited to the patient and condition (e.g., intrathecally, intracerebroventricularly, intrastriatal, by direct injection into specific nerves or ganglia (ganglia), such as the trigeminal ganglion or dorsal root ganglion, or by intracisternal injection via catheterization) at a rate tolerable by the patient until the subject reaches the maximum tolerated dose or until pain symptoms are sufficiently alleviated.

[0262] Example 7. Methods for Treating Pain Associated with Pain Disorders The small interfering RNA (siRNA) molecules of the present disclosure can be used to treat pain disorders, such as pain disorders characterized as erythromelalgia (e.g., episodes of pain, redness, and swelling, typically in the extremities) and / or pain disorders induced by gain-of-function SCN9A gene variants. Non-limiting examples of clinical diagnoses suitable for treatment with the siRNA molecules of the present disclosure include Gerhardt's disease, Mitchell's disease, or Weir-Mitchell disease.

[0263] A subject with erythromelalgia pathology is treated with administration of the siRNA molecule or composition of the present disclosure, formulated as a salt, at a frequency determined by a physician. A physician of ordinary skill in the art can easily determine the effective amount of siRNA molecule to be administered to a mammalian subject (e.g., human) in need thereof. For example, a physician can begin to prescribe a dose of one of the siRNA molecules of the present disclosure at a level lower than that required to achieve a desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Alternatively, a physician can begin a treatment regimen by administering one of the siRNA molecules of the present disclosure at a high dose, and then administer progressively lower doses until a therapeutic effect (e.g., reduction in the expression of SCN9A mRNA) is achieved. In general, a suitable daily dose of one of the siRNA molecules of the present disclosure is the amount of the lowest dose effective to produce a therapeutic effect. The ss-interfering RNA molecules or ds-interfering RNA molecules of the present disclosure can be administered by injection, for example, intrathecal injection, direct injection into a specific nerve or ganglion (ganglia) (e.g., trigeminal ganglion or dorsal root ganglion), or by intracisternal injection via catheter insertion. A daily dose of a therapeutic composition of one of the siRNA molecules of the present disclosure may be administered as a single dose, or as two, three, four, five, six or more doses administered separately at appropriate intervals throughout the day, week, month, or year, optionally in a unit dosage form. Any of the siRNA molecules of the present disclosure can be administered alone, but can also be administered in a pharmaceutical formulation in combination with excipients, carriers, and optionally additional therapeutic agents. The dosage and frequency are determined based on the height, weight, age, sex, and other disorders of the subject.

[0264] The siRNA molecule of the present disclosure is selected by a physician considering its compatibility with a subject.Can select single-stranded or double-stranded siRNA molecules (e.g., unbranched siRNA, bibranched siRNA, tri-branched siRNA, tetra-branched siRNA).Selected siRNA molecule can have antisense strand and sense strand with optimal sequence and RNA modification for patient (e.g., natural and non-natural internucleoside bond, modified sugar, 5' phosphorus stabilizing portion, hydrophobic portion, and / or branched structure).

[0265] The siRNA molecules are delivered by the route best suited to the patient and condition (e.g., intrathecally, by direct injection into specific nerves or ganglia (ganglia), or by intracisternal injection via catheterization) at a rate tolerable by the patient until the subject reaches the maximum tolerated dose or until pain symptoms are sufficiently alleviated.

[0266] Other embodiments All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0267] While the invention has been described in relation to specific embodiments, it will be understood that the invention is capable of further modifications, and this application is generally intended to cover any variations, uses, or adaptations of the invention in accordance with the principles of the invention, including departures therefrom which come within known or customary practice in the art to which this invention pertains and which may be applied to the essential features hereinbefore described, and which fall within the scope of the appended claims.

[0268] Other embodiments are within the scope of the claims.

Claims

1. 1. A small interfering RNA (siRNA) molecule comprising an antisense strand and a sense strand having complementarity to the antisense strand, wherein the antisense strand has sufficient complementarity to hybridize to a region within a sodium voltage-dependent channel alpha subunit 9 (SCN9A) mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

2. 2. The siRNA molecule of claim 1, wherein the antisense strand has at least 70% complementarity to a region of 19, 20, 21, or more contiguous nucleobases within the SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152, and optionally, the antisense strand has at least 70% complementarity to the SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

3. 3. The siRNA molecule of claim 2, wherein the antisense strand has at least 75% complementarity to the region within the SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152, and optionally the antisense strand has at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementarity to the region within the SCN9A mRNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

4. The siRNA molecule of any one of claims 1 to 3, wherein the antisense strand comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within said region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

5. The siRNA molecule of claim 4, wherein the antisense strand comprises 10 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

6. The siRNA molecule of claim 5, wherein the antisense strand comprises 12 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

7. The siRNA molecule of claim 6, wherein the antisense strand comprises 15 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

8. The siRNA molecule of claim 7, wherein the antisense strand comprises 18 to 30 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

9. The siRNA molecule of claim 8, wherein the antisense strand comprises 18 to 25 contiguous nucleotides that are perfectly complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

10. The siRNA molecule of claim 9, wherein the antisense strand comprises 18 to 21 contiguous nucleotides that are completely complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

11. The siRNA molecule of claim 10, wherein the antisense strand comprises 21 contiguous nucleotides that are perfectly complementary to a contiguous polynucleotide segment of equal length within the region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

12. The siRNA molecule of any one of claims 1 to 11, wherein the antisense strand has 9 or fewer nucleotide mismatches to said region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152, and optionally the antisense strand contains 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or only 1 mismatch to said region of the SCN9A RNA transcript having a nucleic acid sequence of any one of SEQ ID NOs: 385-576 and 961-1152.

13. The siRNA molecule of any one of claims 1 to 12, wherein the antisense strand has a nucleic acid sequence that is at least 85% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1 to 192 and 577 to 768.

14. The siRNA molecule of claim 13, wherein the antisense strand has a nucleic acid sequence that is at least 90% identical to any one of the nucleic acid sequences of SEQ ID NOs: 1-192 and 577-768.

15. The siRNA molecule of claim 14, wherein the antisense strand has a nucleic acid sequence that is at least 95% identical to a nucleic acid sequence of SEQ ID NOs: 1-192 and 577-768, and optionally, the antisense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to a nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768.

16. The siRNA molecule of claim 15, wherein the antisense strand has a nucleic acid sequence of any one of SEQ ID NOs: 1-192 and 577-768.

17. The siRNA molecule of any one of claims 1 to 16, wherein the sense strand has a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960.

18. The siRNA molecule of claim 17, wherein the sense strand has a nucleic acid sequence that is at least 90% identical to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960.

19. 19. The siRNA molecule of claim 18, wherein the sense strand has a nucleic acid sequence that is at least 95% identical to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960, and optionally the sense strand has a nucleic acid sequence that is at least 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960.

20. The siRNA molecule of claim 19, wherein the sense strand has a nucleic acid sequence of any one of SEQ ID NOs: 193-384 and 769-960.

21. 21. The siRNA molecule of any one of claims 1 to 20, wherein the antisense strand has a structure represented by formula I, which in the 5'-3' direction is: A-B-(A’) j -C-P 2 -D-P 1 -(C’-P 1 ) k -C’ Formula I; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each A' is of the formula C-P 2 -D-P 2 It is represented by: B is a compound of the formula C-P 2 -D-P 2 -D-P 2 -D-P 2 It is represented by: each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; The siRNA molecule, wherein k is an integer from 1 to 7.

22. The antisense strand has a structure represented by formula A1, which in the 5'-3' direction is: A-S-B-SA Formula A1; 22. The siRNA molecule of claim 21, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

23. 21. The siRNA molecule of any one of claims 1 to 20, wherein the antisense strand has a structure represented by Formula II, which in the 5'-3' direction is: A-B-(A’) j -C-P 2 -D-P 1 -(C-P 1 ) k -C’ Formula II; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each A' is of the formula C-P 2 -D-P 2 It is represented by: B is a compound of the formula C-P 2 -D-P 2 -D-P 2 -D-P 2 It is represented by: each C is a 2'-O-methyl (2'-O-Me) ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-fluoro (2'-F) ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; The siRNA molecule, wherein k is an integer from 1 to 7.

24. The antisense strand has a structure represented by formula A2, which in the 5'-3' direction is: A-S-B-SA Formula A2; 24. The siRNA molecule of claim 23, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

25. the sense strand has a structure represented by Formula III, which in the 5'-3' direction is: E-(A') m -F Formula III; In the formula, E is a compound represented by the formula (C-P 1 ) 2 It is represented by: F is represented by the formula (C-P 2 ), 3 -D-P 1 -C-P 1 -C, (C-P 2 ), 3 -D-P 2 -C-P 2 -C, (C-P 2 ), 3 -D-P 1 -C-P 1 -D, or (C-P 2 ), 3 -D-P 2 -C-P 2 -D; A', C, D, P 1 , and P 2 is as defined in formula II; The siRNA molecule of any one of claims 1 to 24, wherein m is an integer from 1 to 7.

26. The sense strand has a structure represented by formula S1, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-B-S-A-S-A Formula S1; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

27. The sense strand has a structure represented by formula S2, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-BO-O-A-O-A Formula S2; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

28. The sense strand has a structure represented by formula S3, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-B-S-A-S-B Formula S3; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

29. The sense strand has a structure represented by formula S4, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-A-O-A-O-BO-O-A-O-B Formula S4; 26. The siRNA molecule of claim 25, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

30. the antisense strand has a structure represented by Formula IV, which in the 5'-3' direction is: A-(A’) j -C-P 2 -B-(C-P 1 ) k -C’ Formula IV; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each A' is of the formula C-P 2 -D-P 2 It is represented by: B is a compound of the formula D-P 1 -C-P 1 -D-P 1 It is represented by: each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; The siRNA molecule of any one of claims 1 to 20 and 25 to 29, wherein k is an integer from 1 to 7.

31. The antisense strand has a structure represented by formula A3, which in the 5'-3' direction is: A-S-B-S-A-O-B-O-A-O-B-O-A-O-BO-A-O-B-O-A-O-BO-O-A-O-B-O-A-O-B-S-A-S-B-S-A-S-A Formula A3; 31. The siRNA molecule of claim 30, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

32. The sense strand comprises a structure represented by formula V, which in the 5'-3' direction is: E-(A’) m -C-P 2 -F Formula V; In the formula, E is a compound represented by the formula (C-P 1 ) 2 It is represented by: F is represented by the formula D - P 1 -C - P 1 -C, D - P 2 -C - P 2 -C, D - P 1 -C - P 1 -D, or D - P 2 -C - P 2 -D; A', C, D, P 1 , and P 2 is as defined in formula IV; The siRNA molecule of any one of claims 1 to 24, 30, and 31, wherein m is an integer from 1 to 7.

33. The sense strand has a structure represented by formula S5, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-B-O-A-O-B-S-A-S-A Formula S5; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

34. The sense strand has a structure represented by formula S6, which in the 5'-3' direction is: A-S-A-S-A-O-BO-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-BO-O-A-O-B-O-A-O-A Formula S6; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

35. The sense strand has a structure represented by formula S7, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-B-O-A-O-B-S-A-S-B Formula S7; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

36. The sense strand has a structure represented by formula S8, which in the 5'-3' direction is: A-S-A-S-A-O-B-O-A-O-BO-A-O-BO-A-O-BO-O-A-O-B-O-A-O-B-O-A-O-B Formula S8; 33. The siRNA molecule of claim 32, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

37. the antisense strand has a structure represented by formula VI, which in the 5'-3' direction is: A-B j -E-B k -E-F-G l -D-P 1 -C’ Formula VI; In the formula, A is a compound of the formula C-P 1 -D-P 1 It is represented by: Each B is of the formula C-P 2 It is represented by: each C is a 2'-O-Me ribonucleoside; each C' is independently a 2'-O-Me ribonucleoside or a 2'-F ribonucleoside; each D is a 2'-F ribonucleoside; Each E is of the formula D-P 2 -C-P 2 It is represented by: F is the formula D-P 1 -C-P 1 It is represented by: Each G is of the formula C-P 1 It is represented by: Each P 1 is a phosphorothioate internucleoside linkage; Each P 2 is a phosphodiester internucleoside linkage; j is an integer from 1 to 7; k is an integer from 1 to 7; The siRNA molecule of any one of claims 1 to 20, 25 to 29, and 32 to 36, wherein l is an integer from 1 to 7.

38. The antisense strand has a structure represented by formula A4, which in the 5'-3' direction is: A-S-B-S-A-O-A-O-A-O-BO-A-O-A-O-A-O-A-O-A-O-A-O-A-O-B-O-A-O-B-S-A-S-A-S-A-S-B-S-A Formula A4; 38. The siRNA molecule of claim 37, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

39. the sense strand comprises a structure represented by formula VII, which in the 5'-3' direction is: H-B m -I n -A’-B o -H-C Formula VII; In the formula, A′ is a compound of the formula C−P 2 -D-P 2 It is represented by: Each H is represented by the formula (C-P 1 ) 2 It is represented by: Each I is independently a group represented by the formula (D−P 2 ) represented by; B, C, D, P 1 , and P 2 is as defined in formula VI; m is an integer from 1 to 7; n is an integer from 1 to 7; The siRNA molecule of any one of claims 1 to 24, 30, 31, 37, and 38, wherein o is an integer from 1 to 7.

40. The sense strand has a structure represented by formula S9, which in the 5'-3' direction is: A-S-A-S-A-O-A-O-A-O-B-O-BO-O-BO-A-O-BO-O-A-O-A-O-A-O-A-S-A-S-A Formula S9; 40. The siRNA molecule of claim 39, wherein A represents a 2'-O-Me ribonucleoside, B represents a 2'-F ribonucleoside, O represents a phosphodiester internucleoside linkage, and S represents a phosphorothioate internucleoside linkage.

41. The siRNA molecule of any one of claims 1 to 40, wherein the antisense strand further comprises a 5' phosphorus stabilizing moiety at the 5' end of the antisense strand.

42. The siRNA molecule of any one of claims 1 to 41, wherein the sense strand further comprises a 5' phosphorus stabilizing moiety at the 5' end of the sense strand.

43. each 5' phosphorus stabilizing moiety is independently represented by any one of formulas IX-XVI: 【Chemistry 1】 43. The siRNA molecule of claim 41 or 42, wherein Nuc represents a nucleobase selected from the group consisting of adenine, uracil, guanine, thymine, and cytosine, and R represents optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, phenyl, benzyl, or hydrogen.

44. The siRNA molecule of claim 43, wherein the nucleobase is adenine, uracil, guanine, thymine, or cytosine.

45. The siRNA molecule of any one of claims 41 to 44, wherein the 5' phosphorus stabilizing moiety is an (E)-vinyl phosphonate of formula XI.

46. The siRNA molecule of any one of claims 1 to 45, further comprising a hydrophobic moiety at the 5' or 3' end of the siRNA molecule.

47. 47. The siRNA molecule of claim 46, wherein the hydrophobic moiety is selected from the group consisting of cholesterol, vitamin D, or tocopherol.

48. The siRNA molecule of any one of claims 1 to 47, wherein the sense strand is between 10 and 30 nucleotides in length.

49. The siRNA molecule of claim 48, wherein the sense strand is between 10 and 25 nucleotides in length.

50. The siRNA molecule of claim 49, wherein the sense strand is between 12 and 25 nucleotides in length.

51. The siRNA molecule of claim 50, wherein the sense strand is between 12 and 20 nucleotides in length.

52. The siRNA molecule of claim 51, wherein the sense strand is between 12 and 19 nucleotides in length.

53. The siRNA molecule of claim 52, wherein the sense strand is 15 nucleotides in length.

54. The siRNA molecule of claim 52, wherein the sense strand is 16 nucleotides in length.

55. The siRNA molecule of claim 52, wherein the sense strand is 18 nucleotides in length.

56. The siRNA molecule of any one of claims 1 to 55, wherein the length of the antisense strand is between 10 and 30 nucleotides.

57. The siRNA molecule of claim 56, wherein the length of the antisense strand is between 12 and 30 nucleotides.

58. 58. The siRNA molecule of claim 57, wherein the length of the antisense strand is between 15 and 30 nucleotides.

59. 59. The siRNA molecule of claim 58, wherein the length of the antisense strand is between 18 and 30 nucleotides.

60. The siRNA molecule of claim 59, wherein the length of the antisense strand is between 18 and 25 nucleotides.

61. The siRNA molecule of claim 60, wherein the length of the antisense strand is between 18 and 21 nucleotides.

62. The siRNA molecule of claim 61 , wherein the antisense strand is 18 nucleotides in length.

63. The siRNA molecule of claim 61 , wherein the antisense strand is 20 nucleotides in length.

64. The siRNA molecule of claim 61 , wherein the antisense strand is 21 nucleotides in length.

65. 65. The siRNA molecule of any one of claims 1 to 64, which is a branched siRNA molecule.

66. The siRNA molecule of claim 65, wherein the branched siRNA molecule is biantennary, triantennary, or tetraantennary.

67. 67. The siRNA molecule of claim 66, which is a biantennary siRNA molecule, optionally represented by any one of formulas XVII to XIX: 【Chemistry 2】 wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

68. a three-antennary siRNA molecule, optionally wherein the three-antennary siRNA molecule is represented by any one of formulas XX-XXIII; 【Chemistry 3】 67. The siRNA molecule of claim 66, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

69. a four-branched siRNA molecule, optionally wherein the four-branched siRNA molecule is represented by any one of formulas XXIV-XXVIII: 【Chemistry 4】 67. The siRNA molecule of claim 66, wherein each RNA is independently an siRNA molecule, L is a linker, and each X independently represents a branch point moiety.

70. 70. The siRNA molecule of any one of claims 67 to 69, wherein the linker is selected from the group consisting of one or more consecutive subunits of ethylene glycol, alkyl, carbohydrate, block copolymer, peptide, RNA, and DNA.

71. The siRNA molecule of claim 70, wherein the one or more consecutive subunits are between 2 and 20 consecutive subunits.

72. A pharmaceutical composition comprising the siRNA molecule of any one of claims 1 to 71 and a pharma- ceutically acceptable excipient, carrier, or diluent.

73. 73. A method of delivering an siRNA molecule to the central nervous system (CNS) or neurons of a subject experiencing pain or diagnosed as having pain or a pain disorder, comprising administering to the subject a therapeutically effective amount of an siRNA molecule described in any one of claims 1 to 71 or a pharmaceutical composition described in claim 72.

74. 73. A method of treating pain or a pain disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a siRNA molecule according to any one of claims 1 to 71 or a pharmaceutical composition according to claim 72.

75. 75. The method of claim 73 or 74, wherein the pain is neuropathic pain.

76. 75. The method of claim 73 or 74, wherein the pain is nociceptive pain.

77. 75. The method of claim 73 or 74, wherein the pain is post-operative pain.

78. 75. The method of claim 73 or 74, wherein the pain is persistent pain.

79. 75. The method of claim 73 or 74, wherein the pain is inflammatory pain.

80. 75. The method of claim 73 or 74, wherein the pain disorder is Gerhardt's disease, Mitchell's disease, or Weir-Mitchell disease.

81. 75. The method of claim 73 or 74, wherein the subject has been diagnosed with erythromelalgia.

82. 73. A method of reducing SCN9A expression in a subject in need thereof, comprising administering to the CNS of said subject a therapeutically effective amount of an siRNA molecule of any one of claims 1 to 71 or a pharmaceutical composition of claim 72.

83. 83. The method of claim 82, wherein upon administration of the siRNA molecule or pharmaceutical composition to the subject, the subject exhibits a selective reduction in SCN9A expression over the expression of one or more other voltage-gated sodium ion channel genes.

84. The method of any one of claims 73 to 83, wherein the siRNA molecule or pharmaceutical composition is administered to the subject by intrathecal injection or by direct injection into a specific nerve or ganglion.

85. The method of any one of claims 73 to 84, wherein the subject is a human.

86. A kit comprising an siRNA molecule according to any one of claims 1 to 71, or the pharmaceutical composition according to claim 72, and a package insert, the package insert instructing a user of the kit to carry out the method according to any one of claims 73 to 85.